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Tuberculosis continues to kill close to two million people every year. This is due 
to the ease with which the bacteria spreads, the ineffectiveness of the vaccine currently in 
use, as well as the long drug regimen that is required for treatment of the disease. In order 
to develop new vaccines or drugs which require shorter treatment regimens, it is 
important to understand the interaction of the immune system with Mycobacterium 
tuberculosis (Mtb). One of the mechanisms by which Mtb is thought to survive in the 
human host is the inhibition of the apoptosis of infected cells. I was able to identify 
Rv3165c and Rv3167c as two novel anti-apoptotic genes of Mtb. Mtb knock-outs lacking 
Rv3165c or Rv3167c (∆Rv3165c, ∆Rv3167c) failed to inhibit apoptosis of infected 
macrophages and the apoptosis of infected macrophages depended on caspase-8 and 3. 
Inhibiting reactive oxygen species (ROS) production or scavenging ROS inhibited the 
apoptosis of ∆Rv3165c or ∆Rv3167c infected macrophages. ∆Rv3165c and ∆Rv3167c 
failed to upregulate the expression of the only catalase of Mtb, katG. Therefore, it seems 
that Mtb needs to upregulate katG expression in order to neutralize host cell produced 
ROS to inhibit apoptosis. Rv3165c was found to reside mainly in the cell envelope while 
Rv3167c, which is predicted to be a probable transcriptional regulator, was found 
exclusively in the cytosol of mycobacteria. Rv3165c was required for the upregulation of 
Rv3167c expression. These data led to a working model in which Rv3165c sits in the 
plasma membrane of Mtb and detects a signal while Mtb is in the phagosome. This signal 
detection results in upregulation of Rv3167c expression. Increased Rv3167c expression 
enables Rv3167c to change the expression of Mtb genes like katG. Rv3167c upregulates 
expression of anti-apoptotic genes and downregulates the expression of pro-apoptotic 
genes. RNA sequencing and antibody microarray experiments identified the host cell 
components that are differentially regulated in ∆Rv3167c infected cells compared to Mtb 
infected cells. Validation of these targets will help find the host cell pathways Mtb 
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CHAPTER 1 INTRODUCTION 
1.1 TUBERCULOSIS 
Tuberculosis (TB) is an infectious disease caused by the bacterium 
Mycobacterium tuberculosis (Mtb). One third of the world’s population is currently 
infected with Mtb, but only 3-15 % of the infected individuals develop the disease in their 
lifetime (1, 2). There were nearly 8.8 million new cases of tuberculosis and an estimated 
1.4 million people died of tuberculosis in 2010 (3) (Figure 1). People who do not develop 
the disease but still carry live Mtb are said to have latent TB. This latent TB can turn into 
active TB following a weakening of the immune system (3, 4). Although the tuberculosis 
death rate and the number of deaths are declining, the rate of this decline is very slow. 
Another significant statistic is that among women between the ages of 15-44, tuberculosis 
is among the three major causes of death (3). 
TB is spread via aerosols formed when an infected person coughs or sneezes. A 
single bacterium is thought to be enough to cause an infection. When an uninfected 
person inhales droplets carrying Mtb the bacteria gain access to the lung where they are 
phagocytosed by alveolar macrophages through recognition by receptors on their 
surfaces. While Mtb is replicating in the alveolar macrophages the macrophages move to 
the underlying epithelial layer (1). Meanwhile Mtb or dendritic cells (DC) containing 
Mtb antigens move to the lymph nodes in the lung. These DCs can then activate CD4
+ 
T 
cells in the lymph nodes. Activated CD4
+
 T cells then move to the sites of infection in the 
lung to recruit and activate macrophages (5, 6). Blood vessel development increases (via 
increased vascular endothelial growth factor), which helps macrophage recruitment (7, 































Figure 1: Estimated epidemiological burden of TB in 2010. 




 indicates no estimate available. 
a
 Numbers for mortality, prevalence and incidence shown to two significant figures. 
b
 Mortality excludes deaths among HIV-positive TB cases. Deaths among HIV-positive 
TB cases are classified as HIV deaths. 
c
 Best, low and high indicate the point estimate and lower and upper bounds of the 95% 
uncertainty interval. 
d
 Estimates for India have not yet been officially approved by the Ministry of Health & 
Family Welfare, Government of India and should therefore be considered provisional. 








macrophages to form a granuloma. Macrophages can then differentiate into multi-
nucleated giant cells, epithelioid cells, and foamy macrophages. Lymphocytes and a 
fibrous cuff surround the granuloma (1, 8, 9). 
Two to three weeks after infection the mycobacteria are contained and the number 
of mycobacteria stabilizes. The number of blood vessels entering the granuloma 
decreases. This helps decrease the levels of oxygen in the center of the granuloma in 
which the mycobacteria are contained, thus helping to prevent their replication (1). If the 
immune system of the host is compromised during latent TB, (e.g., because of a decrease 
in TNF-α secretion) the granuloma can exhibit caseous necrosis and will eventually 
cavitate. The mycobacteria within the granuloma then can enter the airways of the lungs 
and can be transmitted from the infected person to others (4) (Figure 2). Since formation 
of the granuloma and its later disintegration provides a mechanism to keep Mtb alive and 
then to be transmitted, granuloma formation is suggested to be beneficial for the Mtb 
(10). When TNF-α was neutralized in mice with chronic infection, they could not 
maintain granulomas, the number of bacteria increased 10 fold and the mice survived less 
than 120 days while the control mice lived more than 6 months (11). These data show the 
importance of TNF-α for the survival of the host.      
In the mouse model, following infection the number of Mtb increases in a 
logarithmic fashion until 3-4 weeks and then reaches a stationary level. The leveling of 
the number of Mtb is thought to be due to the onset of adaptive immunity. However, even 
the immunocompetent mice strains succumb to TB (4). Mtb that has been delivered to the 
lungs of the mice can disseminate to the liver and spleen as early as 11 days. The 



















Figure 2: Transmission cycle of Mtb. Live Mtb is inhaled into the lungs where it is 
phagocytosed by alveolar macrophages. The infected macrophages travel into the 
epithelial layer. Blood vessels start to develop around the infected cells and more 
macrophages are recruited. The recruited macrophages, monocytes and neutrophils 
surround the infected macrophages to form a granuloma. Macrophages can then 
differentiate into multi-nucleated giant cells, epithelioid cells, and foamy macrophages. 
Upon weakening of the immune system the granuloma can exhibit caseous necrosis and 
will eventually cavitate. The mycobacteria within the granuloma then can enter the 
airways of the lungs and can be transmitted from the infected person to others. Adapted 




lower than the number in the lungs (4, 12). Following aerosol infection of 
immunocompetent C57BL/6 mice Mtb infects different types of phagocytic cells in the 
lungs. Although it has been long believed that macrophages are the primary niche for 
Mtb, it has been reported that the highest percentage of Mtb infected cells in the lungs 
and the lymphoid nodes were myeloid dendritic cells (DC). The next highest infected cell 
population comprised recruited interstitial macrophages (6). Interestingly, the myeloid 
dendritic cells were among the poorest stimulators of Mtb specific CD4
+
 T cells whereas 
alveolar macrophages were the best stimulators (6). Therefore not only macrophages but 
also other phagocytic cell types must be taken into consideration when trying to 
understand the immune response against Mtb. 
 
1.1.1 Prevention of Tuberculosis 
The vaccine currently in use against TB is Mycobacterium bovis Bacillus 
Calmette–Guérin (BCG), which was generated by passaging a strain of M.bovis for 13 
years (between 1908 and 1921) on potato slices soaked in glycerol (13). After BCG was 
shown to be useful and safe as a vaccine, it was distributed to other countries which then 
maintained and passaged their own strains. For many years the reason for attenuation of 
BCG was not known. When the BCG genome was compared to the genome of parental 
strain M.bovis, several regions of difference were found (14–17) but only “region of 
difference 1” (RD1) was found to be lacking in all of the BCG strains (18, 19). RD1 
contains 9 genes; Rv3871, Rv3872 (PE35), Rv3873 (PPE68), Rv3874 (esxB), Rv3875 
(esxA), Rv3876, Rv3877, Rv3878 and Rv3879c. These genes do not have any known 
functions except esxB, which encodes for the 10kDa culture filtrate protein (CFP10) and 
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esxA, which encodes for the 6kDa early secreted antigenic target (ESAT-6). Deletion of 
RD1 from Mtb leads to decrease in virulence and produces a phenotype similar to BCG, 
indicating the involvement of the RD1 genes in virulence of Mtb (20). 
BCG is effective against the disseminated form of TB in children (21). However 
the efficacy of BCG in protecting adults from pulmonary TB varies from 0 - 80% and 
varies between countries (22). In developing countries the protection efficacy is the 
lowest. The variability of the protective efficacy of BCG might be due to geographical, 
environmental and genetic factors (22, 23). Interestingly, the protective efficacy of BCG 
is lower closer to the equator. One of the reasons for this is thought to be the increased 
concentration of ultraviolet radiation (UVR) towards the equator. The evidence for this 
comes from experiments in which exposure to UVR reduced the development of the 
immune response by BCG in mice (possibly due to increased IL-10 production) and BCG 
vaccinated guinea pigs had reduced resistance against Mtb if they were exposed to UVR 
before or after vaccination (24–26). Another reason is thought to be previous or 
simultaneous infection with parasites leading to a Th2 (Type II helper T cell) immune 
response that prevents an effective response against Mtb. A Th1 (Type I helper T cell) 
response is required to achieve immunity against Mtb, but the presence of a Th2 response 
increases the severity and the onset of the disease (27, 28). Therefore it is suggested that a 
successful vaccine would have to diminish the Th2 responses in addition to inducing Th1 
responses (29). Prior exposure to live environmental mycobacteria greatly decreases the 
effectiveness of BCG. This is thought to be due to prevention of BCG multiplication and 
therefore production of a weak immune response (30). Pre-sensitization of guinea pigs 
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and mice with prior exposure to environmental mycobacteria leads to some protection 
against Mtb (31–33). 
A different explanation for the variable effectiveness of BCG comes from the fact 
that the strains that each country received from Institut Pasteur were passaged many 
times. Studies have shown that the various strains that are used around the world have 
deletions, insertions and SNPs different from each other. On the basis of these differences 
BCG vaccines were divided into the early strains, represented by BCGs Japan, Birkhaug, 
Sweden, and Russia and the late strains, including BCGs Pasteur, Danish, Glaxo, and 
Prague. The major difference between the early and late strains is the lack of RD2 in the 
late strains (16, 17, 34, 35). A recent study showed that the late strains of BCG had more 
genetic variability than the early strains, when compared to the late strain BCG Pasteur. 
Referring to other research done, Brosch et al. suggests that the early BCG vaccine 
strains might have higher protective efficacy than the late strains (36).   
In conclusion, the low efficacy of BCG in preventing tuberculosis has led 
researchers to try to develop new vaccines. The production of effective and low cost 
vaccines for use in areas affected most by tuberculosis is much needed and will save 
many lives. To achieve this goal a better understanding of failure of BCG and new 
strategies to produce effective vaccines are required. 
 
1.1.2 Treatment of tuberculosis 
The treatment of tuberculosis involves a six month minimum drug regimen 
involving 4 drugs, isoniazid, rifampin, pyrazinamide and ethambutol (37). Unfortunately 
strains of Mtb that are drug resistant have emerged through the years due to inconsistent 
 8 
or inappropriate use of drugs. There are multi drug resistant (MDR) Mtb strains that are 
resistant to more than one of the major drugs against Mtb. The estimated number of MDR 
tuberculosis cases in 2010 was 650,000 and 150,000 deaths were caused by MDR 
tuberculosis in 2008 (3). According to estimates, 3.3% of all new tuberculosis cases were 
MDR tuberculosis in 2009. In 2010 in some areas of the world the percentage of MDR 
tuberculosis has been reported to be 28% of new tuberculosis cases (3). The patients who 
have MDR Mtb have to be treated with a second line of drugs that are not only more 
expensive but also can lead to more side effects in the patients. Treatment of MDR Mtb 
can last up to two years, which also increases the cost of the treatment. In addition to 
MDR Mtb, extensively drug resistant (XDR) Mtb strains have emerged. These strains are 
resistant to the second line of drugs as well as the first line. Fifty eight countries reported 
XDR tuberculosis cases (3). This evidence shows the requirement for improved and 
cheaper drugs as well as new vaccine strain(s) (38, 39).  
 
1.1.3 Mycobacterium tuberculosis 
 Mtb is a rod shaped bacillus that has a length between 1-4µm and width between 
0.3-0.6µm (40).  In terms of replication time, mycobacteria are divided into slow growers 
(give colonies on solid media in more than 7 days) and fast growers (give colonies on 
solid media in less than 7 days). M.tuberculosis and M.bovis are slow growers. 
M.fortuitum and M.smegmatis are fast growers (41, 42). The mycobacterial colonies on 
solid media are usually rough, crinkled and white to cream colored (41). The replication 
time of Mtb is around 24 hrs in vitro and in vivo in the lungs of mice (43). The genome of 
Mtb is 4,411,529 bp and contains an estimated 4,000 genes. The genome has a high G+C 
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content of 65.6% (44). The Mtb genome contains many repetitive DNA sequences 
including duplicated housekeeping genes and insertion sequences (44). The cell envelope 
of Mtb consists of a cell membrane and a complex cell wall. The cell wall contains layers 
of peptidoglycan, arabinogalactan, mycolic acids and lipids on the outer part. There are 
lipoarabinomannans and phosphotidylinositol mannosides in the cell wall with their lipid 
moieties inserted in the cell membrane. Due to this complex cell wall, Mtb is resistant to 
many chemicals and therapeutic agents (45). Components of the Mtb cell wall are 
involved in diminishing the immune response (discussed below in 1.2.2). It has been 
shown that the outer cell wall, consisting of mycolic acids and lipids, actually forms a 
symmetrical lipid bilayer (46). It is because of this outer membrane that Mtb can not be 
Gram stained. 
 
1.2 IMMUNE RESPONSE AND MYCOBACTERIA 
1.2.1 Immune response to mycobacteria 
Upon entering the human host, mycobacteria are phagocytosed by macrophages 
through recognition by surface receptors. Human monocyte complement receptors CR1 
and CR3 are involved in the phagocytosis of Mtb. Complement component C3 in the 
serum binds to Mtb and is required for adherence of Mtb to human monocytes and heat 
inactivation of serum significantly reduces Mtb adherence to momocytes (47, 48). Mtb 
Erdman and H37Rv strains require the presence of mannose receptors on the macrophage 
surfaces for adherence (49). Lipoarabinomannan (LAM) of Mtb has been discovered as a 
ligand for the mannose receptor (50). Surfactant protein A (Sp-A), a collectin, increases 
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Mtb attachment to macrophages and its uptake but it is not required for an effective 
immune response against Mtb in a murine infection model (51–53).  
Humans with active TB produce a Th1 response to Mtb and develop granulomas 
to contain the bacteria but cannot kill all the bacteria. However the Th1 responses in 
active TB patients help to restrict the replication and spread of Mtb. In AIDS patients 
Mtb cannot be contained in granulomas and the bacteria replicate and spread from the 
lungs to other organs due to decreased number of CD4
+
 T cells and downregulation of the 
Th1 response (4, 54, 55).  
Toll-like receptors (TLRs) are pattern recognition receptors (PARPs) which detect 
pathogen-associated molecular patterns (PAMPs). TLRs reside in the cell membrane and 
inside the cell, detect ligands and induce immune responses through induction of 
cytokines such as TNF-α, IL-1, IL-6 and IL-12. Upon PAMP recognition, TLRs form 
dimers. Through adaptors like myeloid differentiation primary response gene 88 
(MyD88) and TRIF-related adaptor molecule (TRAM) they activate protein kinases like 
interleukin-1 receptor-associated kinase 1 (IRAK1), leading to changes in gene 
expression through NF-κB (56, 57).  
TLR2 recognizes 19-kDA lipoprotein, lipomannan and phosphatidyl-myo-inositol 
mannoside of Mtb while TLR4 recognizes heat-labile components of the cell wall. The 
19-kDa lipoprotein of Mtb induces apoptosis in macrophages through TLR2 in a caspase-
8 dependent manner (58). Although TLR2 and TLR4 recognize many Mtb components 
and TLR2 knock-out mice show a 50-75% reduction in TNF-α production while TLR4 
knock-out mice show a 30-40% reduction, TLR2 or TLR4 knock-out mice have little 
enhanced susceptibility to Mtb infection. (59). However mice lacking Myd88 (one of the 
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signal transducers for TLRs) were highly susceptible to Mtb infection (60). These data 
indicate potential involvements of other TLRs and/or other Myd88 dependent receptors 
in the immune response against Mtb. 
Intracellular recognition of mycobacteria by host cells depends on intracellular 
proteins called NLRs (Nucleotide binding domain, leucine rich repeat containing) that 
include NODs (Nucleotide binding oligomerization domain containing). NLRs are 
involved in activation of caspase-1 that converts pro-IL-1β and pro-IL-18 to active IL-1β 
and IL-18 (57). NOD1 recognizes γ-D-glutamyl-meso-diaminopimelic acid (ie-DAP) 
from peptidoglycans of Gram negative bacteria and NOD2 recognizes muramyl dipeptide 
(MDP) from peptidoglycans from Gram negative and Gram positive bacteria. When 
peritoneal macrophages from NOD2 knock-out mice were infected with Mtb there was a 
40 to 50% reduction in TNF-α production and a 20 to 25% reduction when peritoneal 
macrophages from NOD1 knock-out mice were used. Blocking the internalization of 
Mtb, which prevents its recognition by NODs also leads to a 40 to 50% decrease in TNF-
α production. When mononuclear cells (MNCs) from patients defective for NOD2 were 
infected with Mtb there was a 65 to 80% reduction in TNF-α secretion. As another 
evidence for the synergistic interaction of TLRs and NLRs, it was shown that addition of 
TLR2 ligand 19-kDa lipoprotein together with NOD2 ligand MDP increased TNF-α 
production from MNCs much more than the total of the ligands by themselves (59). 
While it was shown that macrophages and DCs lacking NOD2 were impaired in 
their ability to produce inflammatory cytokines (TNF-α and IL-12) and NO upon 
infection with Mtb, it was also found that NOD2 deficient mice were no more susceptible 
to Mtb infection than wild-type mice and had similar bacterial counts in the lungs up to 8 
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weeks after infection (61). However, it was also reported that NOD2 deficient mice have 
significantly higher bacterial counts by 6 months and succumb to death earlier than wild-
type mice after Mtb infection (62). So, although in vitro NOD2 plays a role in cytokine 
production, especially synergistically with TLR2 it seems to be dispensable for the 
immune response against Mtb and the control of infection during the early stages of 
infection. In the case of TNF-α, depletion of TNF-α by a monoclonal antibody in 
C57BL/6 mice causes mice to succumb to death faster following infection with Mtb. 
Similarly, infection of C57BL/6 mice lacking TNF-α receptor with Mtb causes them to 
succumb to death faster (63). Therefore TNF-α is required for a successful immune 
response against Mtb in mice. The fact that NOD2 deficient mice are not more 
susceptible to Mtb during early stages of infection although NOD2 deficient 
macrophages produced significantly less TNF-α upon Mtb infection in vitro suggests two 
possibilities. One possibility is that even though TNF-α production by macrophages is 
also decreased in vivo, it is still enough for an effective immune response. The other 
possibility is that the in vitro result does not reflect conditions in vivo and NOD2 knock-
out mice can produce similar levels of TNF-α in response to Mtb, at least during the early 
stages of infection. It is also possible that TNF-α production by another cell type in 
NOD2 knock-out mice is not affected and that is enough for the host response. 
   
1.2.2 Prevention of phagosome maturation by Mtb 
Mtb prevents the fusion of the phagosome with lysosomes and thus prevents 
phagosome maturation (64, 65). Pathogenic mycobacteria utilize different strategies to 
prevent the phagosome maturation in order to survive, replicate in the phagosome, cause 
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necrosis of the infected cells and disseminate (66, 67). The strategies adapted by 
pathogenic mycobacteria involve manipulation of the host cell signaling that leads to the 
fusion of the lysosome with the phagosome. 
Coronin 1 is a protein identified in the membranes of phagosomes that contain 
live mycobacteria after infection of murine macrophages. Coronins are thought to be 
involved in the regulation of the actin cytosekeleton (68). When macrophages were 
infected with live mycobacteria, coronin 1 was present on phagosomes but when the 
macrophages were infected with dead mycobacteria, coronin 1 left the phagosomes, 
which was followed by the fusion of phagosomes with lysosomes and the degradation of 
the mycobacteria (69). Coronin 1 is dispensable for regulation of the actin cytoskeleton 
but activates the Ca
2+
-dependent phosphatase calcineurin. Active calcineurin then blocks 
the fusion of phagosomes with lysosomes (70). Kupffer cells in the liver do not express 
coronin1. Following infection of Kupffer cells all mycobacteria were located in 
phagolysosomes and were then degraded. Expression of coronin 1 in a nonmacrophage 
cell line was sufficient to prevent lysosomal fusion of the mycobacterial phagosome, 
allowing survival of mycobacteria (69). These experiments showed the ability of 
mycobacteria to recruit coronin 1 to phagosomes to prevent their fusion with lysosomes. 
Mannose capped lipoarabinomannan (ManLAM) of Mtb is a glycolipid that is a 
component of the Mtb cell wall. ManLAM from Mtb prevents phagosome maturation, 
probably by blocking the generation of phosphatidylinositol 3-phosphate  (PI3P) and its 
recruitment to the phagosomal membrane (71–73). PI3P is involved in the recruitment 
and functioning of PI3P binding domain containing proteins that are involved in 
membrane trafficking and phagosome maturation (74). ManLAM also inhibits the 
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activation of mitogen-activated protein kinases (MAPK) in humans (75). MAPK 
activation elicits the synthesis of TNF-α and induction of iNOS (inducible nitric oxide 
synthase) (76–78). By blocking MAPK in monocytes, ManLAM prevents the production 
of TNF-α and nitric oxide. TNF-α is a major cytokine that promotes apoptosis in 
mycobacteria infected macrophages (79). These data indicate that the ManLAM of Mtb 
indirectly inhibits apoptosis. Pathogenic mycobacteria also have strategies to block the 
bactericidal effects of NO and the recruitment of the iNOS to the phagosome (80). Mtb 
uses its proteasome to defend itself against the destructive effects of NO and mutants 
with transposon insertions in proteasome associated genes are susceptible to acidified 
nitrite (81, 82). 
Mycobacteria also have proteins that prevent phagosome maturation. One of them 
is the mycobacterial protein kinase G (pknG). A pknG knock-out of Mycobacterium bovis 
BCG colocalized with lysosomes and could not resist destruction by macrophages, unlike 
wild type M.bovis BCG. pknG was present in both the lumen of the phagosomes and the 
cytosol of the infected macrophages and inhibited phagosome lysosome fusion (83). The 
presence of pknG in the host cytosol suggests it might interefere with host cell signaling 
in order to prevent phagosome maturation. pknG autophosphorylates but this does not 
affect its kinase activity. Autophosphorylation of pknG prevents fusion of Mtb containing 
phagosomes with lysosomes (84). Expression of PknG in M.smegmatis increases the 
persistence of M.smegmatis in mice (85). PknG mutant of Mtb is less virulent in SCID 
mice (86). This evidence suggests that by preventing phagosome lysosome fusion, pknG 




Apoptosis is a form of programmed cell death, characterized by shrinkage of 
cytoplasm, condensation of chromatin, fragmentation of chromosomal DNA, formation 
of cell membrane blebs and formation of apoptotic bodies (87) (Figure 3). Apoptosis is 
the predominant method for the removal of unwanted cells in the immune and central 
nervous systems. Removal of certain cells during embryonic development or upon 
damage is also achieved through apoptosis (88). Apoptosis is preferred over necrosis in 
these situations because necrosis can damage other healthy cells and cause inflammation, 
whereas the apoptotic bodies that are formed are taken up by neighboring phagocytes and 
thus damage is prevented (89, 90). Certain mutations can lead to decreased levels of 
apoptosis and therefore promote survival of cancer cells (88). Mutations of caspase genes 
that inhibit their activity or downregulation of caspase gene expression are common in 
certain cancers (91, 92). On the other hand, flaws in the removal of apoptotic bodies can 
lead to autoimmune diseases (93). 
Apoptosis is carried out by caspases, which are zymogenic proteases. They cleave 
various cellular substrates that in turn lead to the phenotypes seen during apoptosis (94, 
95). There are two pathways for caspase activation, an extrinsic and an intrinsic pathway 
(88) (Figure 4). The extrinsic pathway involves the binding of ligands to cell surface 
receptors, which is followed by recruitment and binding of cellular proteins to the 
cytoplasmic side of the receptors, thus leading to activation of initiator caspases 2, 8, 9, 
and 10 and effector caspases 3, 6, and 7 (96, 97). TNF-α and Fas-L are two of the ligands 
which bind to their receptors, TNF-α receptor-1 (TNFR1) and Fas respectively, in this 
pathway (98). Both of these receptors have death domains on their cytoplasmic sides,  
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which allow them to interact with other proteins that have death domains. TNFR1 
interacts with TNFR-associated death domain (TRADD) and Fas interacts with Fas-
associated death domain (FADD) (98). FADD has another domain called death effector 
domain (DED), which allows it to interact with caspase-8 (caspase-8 also has DED). This 
interaction causes the activation of caspase-8 which then leads to the activation of 
downstream caspases such as caspase-3 (87). 
The TRADD that interacts with TNFR1 can also interact with FADD and lead to 
the activation of caspases (99). TRADD can also interact with RIP1 and TRAF2 to 
activate anti-apoptotic signals. TNF-α can interact with another receptor, TNFR2 and this 
interaction leads to activation of NF-κB, which leads to production of anti-apoptotic 
proteins (101). Fas can also interact with Daxx to activate it, which then activates 
apoptosis signal-regulating kinase 1 (ASK1). ASK1 is a MAPKKK that activates c-jun 
N-terminal kinase and p38 MAPK signaling pathways followed by apoptosis (102–104). 
The intrinsic pathway of caspase activation involves the release of cytochrome c 
from the mitochondria after the permeabilization of its outer membrane upon apoptotic 
stimuli. The release of cytochrome c is regulated by the Bcl-2 protein family, some of 
which promote and some of which inhibit the release of cytochrome c (105). Depending 
on the cell type, cytochrome c is usually proapoptotic. The release of cytochrome c in 
some cases is required for events like cellular differentiation (106). The released 
cytochrome c, together with Apaf-1 and pro-casspase-9, forms a complex that has been 
called the apoptosome. The apoptosome then activates the downstream effector caspases 
(107, 108). 
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There is crosstalk present between the two caspase activation pathways. Caspase-
8, which is a part of the extrinsic pathway can cleave and activate the protein Bid which 
is a Bcl-2 protein family member. The activation of Bid promotes the release of 
cytochrome c from mitochondria and activation of caspase-9 (108). Therefore it is 
possible to observe caspase-9 activation following extrinsic caspase activation. 
 
1.3.1 Role of ROS in apoptosis 
Reactive oxygen species (ROS) are used by the cells in both defense against 
pathogens and regulation of cell signaling (109–111). ROS are produced by mitochondria 
as well as Nox and Duox enzymes that are on the membrane, using NADPH and oxygen 
(112–114). As signaling molecules, ROS can induce prolonged JNK activation and TNF-
α induced apoptosis in certain cells. As another strategy, NF-κB activation can be 
blocked by ROS and this prevents transcription of survival genes and promotes cell death 
(Figure 5) (115). ROS are able to inhibit the activity of some NF-κB activators since they 
contain specific cysteines that can be oxidized and lose their activity afterwards (110). 
Thus, increased levels of ROS promote apoptosis by inducing prolonged JNK activation 
and blocking NF-κB activation. 
 
1.3.2 Apoptotic response to bacterial pathogens 
Some pathogens induce apoptosis while others inhibit apoptosis. Pathogens can 
employ toxins and virulence factors for these purposes (116, 117). Pathogens also affect 
host cell apoptosis through manipulation of cell survival pathways that include NF-κB 


















Figure 5: ROS mediates the balance between the pro-apoptotic and anti-apoptotic 
phenotypes induced by TNF-α.  Increased levels of ROS can induce prolonged JNK 
activation that leads to apoptosis and blocks NF-κB activation to promote apoptosis. 






κB to inhibit apoptosis. Chlamydia also inhibits apoptosis by preventing cytochrome c 
release and thus promotes its own survival (118, 119). Chlamydia pneumoniae causes an 
increase in expression of the anti-apoptotic host gene mcl-1 in infected cells (120). 
Rickettsia rickettsii is another pathogen that inhibits host cell apoptosis by increasing NF-
κB activation to promote its own survival. Inhibition of NF-κB activation in infected cells 
results in activation of caspases 8, 9 and 3, followed by an increase in apoptosis (121). 
Salmonella typhimurium uses its protein AvrA to inhibit apoptosis in macrophages (122). 
AvrA is a 33 kDa protein secreted by Salmonella typhimurium that has been 
characterized as an acetyltransferase that can inhibit JNK activation in host cells (123).  
Yersinia pestis, Yersinia enterocolitica, and Yersinia pseudotuberculosis have  
plasmids that contain genes for a type III secretion system (TTSS) that is necessary for 
their virulence. TTSS is responsible for secretion of Yop proteins (124). YopJ of Yersinia 
pseudotuberculosis inhibits MAPK and NF-κB pathways, and induces apoptosis of 
infected macrophages (125–128). In the meantime, the actions of other Yop proteins 
affect the cell signaling network and the organization of the cytoskeleton host cell to 
prevent phagocytosis of the bacteria (124). These actions of YopJ and other Yop proteins 
are thought to help the survival of the bacteria by inhibiting the innate immune response 
of the host cells (128).  
Bordetella pertussis, the bacterium that causes whooping cough, secretes many 
adhesins to attach to the host ciliated cells and toxins to cause lesions and host cell death 
after it arrives in the host respiratory tract (129). Bordetella pertussis induces apoptosis of 
J774A.1 cells and murine alveolar macrophages. This mechanism is thought to benefit 
Bordetella pertussis by eliminating macrophages that can kill it in the lungs so that it can 
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infect the epithelial cells and replicate. The pro-apoptotic phenotype of Bordetella 
pertussis depends on one of the secreted toxins, adenylate cyclase-hemolysin (AC-Hly) 
(130). AC-Hly consists of an adenylate cyclase domain and a pore-forming repeat in a 
toxin hemolysin domain. AC-Hly is secreted by a type I secretion mechanism (131). 
Upon entrance into the cell, the adeylate cyclase domain binds to calmodulin and is 
activated to catalyze the synthesis of cAMP from ATP (132). Increased amounts of 
cAMP disrupt cellular functions and induce apoptosis (130).  
Streptococcus pneumoniae induces apoptosis of alveolar macrophages which 
leads to the clearance of the bacteria from the lungs. Inhibition of caspase activation in 
the S. pneumoniae infected host cells decreased the rate of apoptosis and inhibited the 
killing of S. pneumoniae (133). S.pneumoniae inhibits the upregulation of expression of 
the anti-apoptotic protein Mcl-1 and blockage of this inhibition results in decreased 
apoptosis and killing of S.pneumoniae. Infection of Mcl-1 transgenic mice with S. 
pneumoniae led to decreased apoptosis of alveolar macrophages and better survival of the 
bacteria compared to infection of nontransgenic mice (134). 
As shown in the examples above, inhibition of apoptosis by bacterial pathogens 
promotes their survival and inhibition of the innate immune response. Inhibition of 
apoptosis is achieved by different strategies, including activation of NF-κB, inhibition of 
JNK activation and increasing expression of host anti-apoptotic proteins. Promotion of 
apoptosis is also employed by bacterial pathogens to remove cells that can kill them. 




1.4 APOPTOTIC RESPONSE TO MTB 
Apoptosis of infected macrophages is suggested to be a way to eliminate suitable 
growth environments for Mtb (79, 135). Virulence of the mycobacterial strains has an 
inverse relationship with their ability to induce apoptosis. Virulent strains of 
mycobacteria, such as M.tuberculosis H37Rv, Erdman and M.bovis wild type were 
shown to induce significantly less apoptosis in macrophages than avirulent strains, 
including M.tuberculosis H37Ra, M.bovis BCG and M. kansasii (135, 136).  The 
relatively high rate of apoptosis of macrophages by avirulent strains was not due to 
higher intracellular growth. On the contrary while the virulent strains increased in 
number, the avirulent strains decreased in number, which suggests that the apoptosis of 
macrophages may help decrease the number of intracellular mycobacteria (135). 
Induction of apoptosis by Fas ligand (FasL) aids in the killing of intracellular Mtb by 
human blood monocyte derived macrophages (137).  
Inside the phagosomes of macrophages, the mycobacteria are safe from being 
presented to T cells through MHCI and CD1. Apoptosis is a way for the host to overcome 
this problem. Following apoptosis, the apoptotic blebs are taken up by uninfected 
macrophages and dendritic cells. The apoptotic blebs contain mycobacterial proteins and 
cell wall lipids (138). The dendritic cells that have taken up the apoptotic blebs then 
present the enclosed mycobacterial antigens to CD8
+ 
T cells via MHCI and CD1. This 
pathway of cross-presentation leads to the activation of CD8
+
 T cells (138–140). CD8
+
 T 
cells are important in the immune response against Mtb as mice lacking CD8
+
 T cells are 
more susceptible to infection with Mtb. CD8
+
 T cells are also responsible for macrophage 
activation via production of IFN-γ and killing of mycobacteria infected cells (138, 141). 
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Vaccination of mice with apoptotic blebs from mycobacteria-infected macrophages was 
also shown to protect against tuberculosis (140). 
 
1.4.1 Inhibition of apoptosis by Mtb 
Mtb can inhibit apoptosis that is induced by other factors. FasL by itself is enough 
to induce apoptosis in macrophages. It was shown that when Mtb infected macrophages 
were treated with FasL the percentage of apoptotic cells had decreased compared to 
uninfected cells. It was also found that in Mtb infected macrophages, the expression of 
Fas on the surface is down regulated, which can explain the decrease in apoptosis 
following FasL treatment (137).  
TNF-α can also induce apoptosis. Infection of macrophages with both virulent 
and avirulent Mtb were shown to induce TNF-α secretion from the cells. However, 
infection with virulent Mtb also led to production of soluble TNF-α receptor 2 (sTNFR2) 
(142). This process can decrease the amount of TNF-α interacting with TNFR, which 
would lead to inhibition of apoptosis of Mtb infected cells. 
Infection of cells with mycobacteria results in the up-regulation of anti-apoptotic 
genes of the Bcl-2 family, such as mcl-1 (143) and bfl-1 (144). Reducing Mcl-1 protein 
expression in the infected cells by using antisense oligonucleotides leads to an increase in 
apoptosis of the cells infected with virulent Mtb. Reducing Mcl-1 amount also leads to 
decreased survival of virulent Mtb inside the cells (143). In mice, after infection with 
Mtb, the expression of the anti-apoptotic gene bcl-2 increased, whereas the expression of 
pro-apoptotic gene bax decreased (145). BCG infection can inhibit S-nitroso-N-
acetylpenicillamine induced apoptosis in macrophages from wild type mice by more than 
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50% but cannot inhibit apoptosis induced in macrophages from A1 knock-out mice, 
which lack the anti-apoptotic gene bfl-1 (144). These data show that mycobacteria can 
manipulate regulation of both the host genes and proteins to increase anti-apoptotic gene 
expression and/or decrease pro-apoptotic gene expression in order to inhibit apoptosis 
and thus survive inside the host cell. Since it was shown that avirulent mycobacteria 
induced more apoptosis, these strains would be expected to lead to higher cellular 
immunity via cross-presentation to CD8
+
 T cells. Production of new avirulent vaccine 
strains of mycobacteria that induce high levels of apoptosis can be achieved by 
identification of mycobacterial anti-apoptotic genes that are responsible for inhibition of 
apoptosis in host cells. Identification of anti-apoptotic mycobacterial genes can also 
reveal new targets for the use of antimycobacterial compounds.  
 
1.4.2 Anti-apoptotic genes of Mtb 
Previous work by our group and others has identified several anti-apoptotic genes 
of Mtb. nuoG (encodes NuoG subunit of the type I NADH (nicotinamide adenine 
dinucleotide)-dehydrogenase of Mtb), secA2 (encodes a protein required for the secretion 
of superoxide dismutase A [SodA], Alpha-crystallin [Acr] and Rv0390) and pknE 
(protein kinase E, a serine threonine protein kinase) genes are required for inhibition of 
apoptosis by Mtb (146–148). NuoG inhibits the accumulation of phagosomal ROS, 
prevents an increase in TNF-α secretion and inhibits host cell apoptosis (149). SecA2 
functions in the secretion of proteins SodA, Acr, Rv0390 and KatG. SecA2 mutant of Mtb 
is less virulent in SCID mice (150).The anti-apoptotic property of SecA2 seems to come 
from its involvement in secretion of the protein SodA, since re-establishment of SodA 
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secretion in secA2 knock-out Mtb reversed the pro-apoptotic phenotype of the secA2 
knock-out (146). KatG secretion is also defective in secA2 knock-out Mtb (150), but 
KatG was not involved in apoptosis inhibition as re-establishment of SodA secretion was 
enough to reverse the pro-apoptotic phenotype of secA2 mutant strain (146). SodA 
enzyme converts superoxide radicals to hydrogen peroxide and oxygen, thereby 
protecting the bacteria against oxidative damage (151). An Mtb mutant that had reduced 
SodA levels is pro-apoptotic and less virulent than wild-type Mtb (151). The pknE 
promoter is induced when the cells are exposed to nitric oxide donors and pknE is 
involved in regulating the host cell arginase pathway by increasing arginase 1 and 
arginase 2 activities for survival of Mtb (152). Increased arginase 1 and arginase 2 
activities lead to decreased NO production as they compete with iNOS for L-arginine 
(153). pknE is also involved in inhibiting expression of several TLRs (152).  
The common point of these three anti-apoptotic genes is their role in neutralizing 
or preventing ROS or NO species. This highlights the involvement of ROS and NO in 
promoting apoptosis. On the other hand, Mtb has proteins working to inhibit apoptosis by 
neutralizing or preventing ROS or NO species. 
 
1.4.3 Identification of novel anti-apoptotic genes of Mtb 
In order to identify Mtb genes that are responsible for the inhibition of apoptosis, 
a gain-of-function genetic screen was performed using a strain of non-pathogenic 
M.smegmatis (147). The mc
2
155 strain that was used has the ability to grow fast and is 
also easily transformable (154). The human monocytic leukemia cell line THP-1 was 
used as host cells for this screen. Early studies showed that infection of THP-1 cells with 
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M.smegmatis led to a much higher level of apoptosis (~ 40%) compared to uninfected 
(less than 5%) or BCG infected cells (less than 10%) just 16 hr after infection (147). For 
the gain of function screen, 312 Mtb genomic fragments were used to transform 
M.smegmatis. The 312 M.smegmatis clones were then used to infect THP-1 cells. Five 
clones with reduced apoptosis were identified. The cosmids that enabled M.smegmatis to 
inhibit apoptosis were extracted from the clones and were used to transfect M.smegmatis 
again. This was done to confirm that the decreased apoptosis was due to the presence of 
the cosmids in M.smegmatis. The decrease in apoptosis was reproducible for two of the 
five clones (147). 
Although the 2 cosmids were able to reduce the pro-apoptotic phenotype of 
M.smegmatis, M.smegmatis clones with the cosmids still induced high levels of apoptosis 
(between 15 and 25%) (147). This was probably due to the ability of M.smegmatis to 
strongly induce apoptosis faster than other mycobacteria. To better assess the effects of 
the cosmids in inhibition of apoptosis induction, M.kansasii, a facultative pathogenic 
species was used. M.kansasii induces high levels of apoptosis but is slower in killing the 
host cells (significant levels of apoptosis induced after 3 days). The 2 cosmids that 
showed consistent decrease of apoptosis in M.smegmatis as well as the empty cosmid 
vector were transformed into M.kansasii. The clones with these cosmids induced 
significantly lower amounts of apoptosis compared to the empty cosmid containing 
M.kansasii (147). 
To find smaller regions inside one of the cosmids (named J21) that are 
responsible for the inhibition of apoptosis, four sections within J21 were knocked out in 










Figure 6: The J21 cosmid. The J21 cosmid that has been identified as a region that 
contains anti-apoptotic genes has the Mtb genomic sequence from 3511000bp to 

















discovery of anti-apoptotic gene nuoG, the 7/10 region was found to contain anti-
apoptotic genes (Velmurugan K, unpublished) (Figure 7).  As expected from an apoptosis 
inducing knock-out strain, ∆7/10 was shown to be less virulent than wild type Mtb in a 
survival experiment using SCID mice (Velmurugan K, unpublished) (Figure 8). The 7/10 
region contains five complete genes: MoxR3, Rv3167c, Rv3165c, Rv3166c and Rv3163c. 
Rv3163c is a secreted protein that previous data suggests is not involved in apoptosis (29; 
Velmurugan K, unpublished).  Individual knock outs of MoxR3, Rv3167c, Rv3165c, and 
Rv3166c were made via phage transduction and were used in THP-1 infections. Initial 
data showed increased apoptosis upon infection with ∆Rv3165c and ∆Rv3167c (Miller J, 
unpublished) (Figure 9). Therefore, the preliminary data suggested that Rv3165c and 
Rv3167c were the anti-apoptotic genes in the 7/10 region. The research that is presented 
here was performed to confirm that ∆Rv3165c and ∆Rv3167c were pro-apoptotic, to find 
the pathways involved in apoptosis of ∆Rv3165c and ∆Rv3167c infected cells and to 
characterize Rv3165c and Rv3167c. 
 
1.5 SUMMARY AND SIGNIFICANCE 
Mtb continues to kill millions of people every year (3). One of the reasons of 
failure in the eradication of Mtb is the low success rate of the current BCG vaccine (22, 
23). Another reason is the lack of drugs that can kill Mtb in weeks compared to the 
current drugs that take months to be effective (37). That is why it is necessary to develop 
new and effective prevention and treatment methods against TB. To achieve this goal it is 
necessary to understand the mechanisms by which Mtb survives in the host. One of these 
mechanisms might be the prevention of apoptosis of infected host cells. A better  
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Figure 7: 3/4 and 7/10 regions of the J21 cosmid contain anti-apoptotic genes. Mtb 
and knock-outs lacking the 3/4 or 5/8 or 7/10 regions were used to infect THP-1 
macrophages. Mtb knock-outs lacking the 3/4 or 7/10 regions were found to induce 
significantly more apoptosis compared to Mtb. Data are the mean ± SEM of a 
representative experiment performed in duplicate. UT, untreated; ns, not significant; ***, 




















































Figure 8: Deletion of the 7/10 region in Mtb reduces its virulence in SCID mice. Five 
SCID mice were infected by injection of 10
6
 Mtb or ∆7/10 in the tail and monitored. Mtb 









 days. Log-rank test found the curves to be significantly different. **, 0.001< p < 0.01 

















































Figure 9: Preliminary experiments indicate Rv3165c and Rv3167c genes as the anti-
apoptotic genes in the 7/10 region. THP-1 macrophages were infected with Mtb and the 
knock-outs for 5 days. The cells were collected and stained with TUNEL to determine the 
% of apoptotic cells. Data are the mean ± SEM of a representative experiment performed 








































understanding of this mechanism will help in the development of vaccine strains that do 
not prevent host cell apoptosis and hence induce a better immune response. Also, 
identification of Mtb components that inhibit apoptosis can reveal new targets for drugs. 
Drugs that target anti-apoptotic components of Mtb would help the immune system to kill 
the intracellular Mtb that is hard to target with other drugs. Previously a genomic DNA 
region of Mtb was identified to contain anti-apoptotic genes (147). The goals of my 
research were to identify some of the genes in this region, characterize the genes and 

















CHAPTER 2 MATERIALS AND METHODS 
2.1 MATERIALS 
SCID mice (BALB/c background) were from Jackson Laboratories (Bar Harbor, 
ME). The anti-myc antibody (9E 10) developed by [Bishop, J.M.] was obtained from the 
Developmental Studies Hybridoma Bank developed under the auspices of the NICHD 
and maintained by The University of Iowa, Department of Biology (Iowa City, IA). 
Cleaved caspase-8, cleaved caspase-9, cleaved caspase-3 antibodies were purchased from 
Cell Signaling Technology® (Danvers, MA). Anti-actin antibody was purchased was 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-GroEL, anti-LAM, anti-
DnaK, and anti-FAP antibodies were purchased from Colorado State University through 
the TB Vaccine Testing and Research Materials Contract as part of NIH, NIAID Contract 
No. HHSN266200400091C (Fort Collins, CO). Horse radish peroxidase-conjugated goat 
anti-mouse IgG, horse radish peroxidase-conjugated goat anti-rabbit IgG, horse radish 
peroxidase-conjugated donkey anti-goat IgG, alkaline phosphatase conjugated 
streptavidin (Streptavidin-AP) were purchased from Jackson ImmunoResearch 
Laboratories Inc. (West Grove, PA). Cytometric Bead Array kit for human inflammatory 
cytokines was purchased from BD Biosciences (San Jose, CA). N-acetyl cysteine, and 
Hygromycin B were purchased from EMD Chemicals (Philadelphia, PA). FLICA™ kits 
were purchased from ImmunoChemistry Technologies LLC (Bloomington, MN). In Situ 
Cell Death Detection Kit, Fluorescein for TUNEL and LightCycler® 480 SYBR Green I 
Master for qPCR, PhosSTOP phosphatase inhibitor cocktail tablets and cOmplete, Mini, 
EDTA-free protease inhibitor cocktail tablets were purchased from Roche (Indianapolis, 
IN). Ribo-zero™ and ScriptSeq™ mRNA-Seq Library Preperation kits for RNA 
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sequencing were purchased from Epicentre (Madison, WI). Human CCL3/MIP-1 alpha 
DuoSet and Human CCL20/MIP-3 alpha DuoSet ELISA kits were purchased from R&D 
Systems® (Minneapolis, MN). Lysis buffer for protein microarray was supplied by 
Kinexus (Vancouver, Canada). Electroporation cuvettes were purchased from VWR 
(Bridgeport, NJ). Fetal calf serum was purchased from Thermo Scientific (Logan, UT). 
Human serum was purchased from Gemini Bio-Products (West Sacramento, CA). 
Gentamicin, and TRIzol® Reagent were purchased from Invitrogen™ (Grand Island, 
NY). Three well slides were purchased from Electron Microscopy Sciences (Hatfield, 
PA). BrightStar® Psoralen-Biotin Kit and BrightStar® BioDetect™ Nonisotopic 
Detection Kit for Southern blots, and TURBO DNA-free™ were purchased from Ambion 
(Grand Island, NY). AlkPhos Direct™ hybridization buffer was purchased from 
Amersham (Piscataway, NJ). Centriplus® YM-3 centrifugal filters were purchased from 
Millipore™ (Billerica, MA). Thermo Scientific SuperSignal West Femto Substrate, 
Thermo Scientific SuperSignal West Pico Chemiluminescent Substrate, Thermo 
Scientific Pierce BCA Protein Assay Kit, Costar 96-Well EIA/RIA plates for ELISA, 
Triton® X-100, Phorbol 12-myristate 13-acetate (PMA), kanamycin, streptomycin, 
Tween®-80, and Thermo Scientific Phusion® RT-PCR Kit for reverse transcription were 
purchased from Fisher (Pittsburgh, PA). Proteinase K was purchased from Fermentas 
(Glen Burnie, MD). Staurosporine, xanthine oxidase, xanthine, glutathione, DPI, 





2.2 BACTERIA AND CULTURE CONDITIONS 
M. tuberculosis H37Rv (ATCC 25618) was obtained from the American 
Type Culture Collection (Manassas, VA). Middlebrook 7H9 medium supplemented with 
0.5% glycerol, 0.05% Tween-80, and 10% ADS (Albumin, 5% w/v, dextrose, 2% w/v, 
NaCl, 0.85% w/v) or ADC (Albumin, 5% w/v, dextrose, 2% w/v, catalase, 0.003% w/v, 
NaCl, 0.85% w/v) was used to grow Mtb strains (155). Mycobacteria containing plasmids 
with antibiotic resistance genes were grown in the presence of 50µg/ml hygromycin or 
40µg/ml kanamycin or 20µg/ml streptomycin.  
 
2.3 IN VITRO HYDROGEN PEROXIDE PRODUCTION 
Bacteria were collected by centrifugation and resuspended in PBS to adjust their 
concentration to 10
6
 bacteria/ml. To produce hydrogen peroxide in vitro, 250µM xanthine 
and 0.1U/ml xanthine oxidase were added to the bacteria and the bacteria were shaken for 




2.4 CREATION OF COMPLEMENTS OF KNOCKOUTS 
For complementation of the ∆Rv3165c knockout, the sequence from 200bp 
upstream of Rv3165c to 110bp downstream of Rv3165c was cloned into the integrating 
vector pDB60 that contains a streptomycin resistance gene. The insertion of the correct 
sequence was confirmed by plasmid sequencing. The plasmid was electroporated into 
∆Rv3165c and colonies were grown and selected as mentioned below. For 
complementation of ∆Rv3167c knockout, the sequence from 60bp upstream of Rv3167c 
to the 3’ end of Rv3167c was cloned into the extrachromosomal expression vector 
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pmv261. The plasmid was electroporated into ∆Rv3167c and colonies were grown and 
selected as mentioned below. 
 
2.5 CREATION OF RV3165C-MYC AND RV3167C-MYC EXPRESSING BCG 
To make Rv3167c-myc, the sequence from 60bp upstream of Rv3167c to the 3’ 
end of Rv3167c with the myc tag sequence was cloned into the extrachromosomal 
expression vector pmv261. The plasmid was electroporated into BCG and colonies were 
grown and selected as mentioned below. To make Rv3165c-myc, the sequence from 50bp 
upstream of Rv3165c to the 3’ end of Rv3165c with the myc tag sequence was cloned into 
the extrachromosomal expression vector, pmv261. The plasmid was electroporated into 
BCG and colonies were grown and selected as mentioned below. 
 
2.6 ELECTROPORATION OF PLASMIDS 
To electroporate plasmids, 5ml of late log phase culture was centrifuged at 2000g 
for 10 min and the cells were washed three times with an equal volume of wash solution 
(10% glycerol with 0.05% Tween-80). The final pellet was resuspended in 1/10
th
 the 
original volume of wash solution. Bacteria (400µl) were added to a 2mm electroporation 
cuvette containing 2-5µl of plasmid. Bacteria were electroporated at 2.5kV; 25uFD; 
1000Ω in a BioRad GenePulser Xcell™ electroporator. 7H9 (1ml) medium was added to 
the bacteria, which were allowed to recover for 3hr for M. smegmatis or 24hr for slow 
growers (Mtb, BCG, M. kansasii). The cells were then plated on 7H10 agar plates 
containing the appropriate selective medium and incubated for 3-4 days (M.smegmatis) or 
3 weeks (Mtb, BCG) at 37 
o
C. Resulting colonies were grown in 7H9 medium with 
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appropriate antibiotic and the cultures were screened by PCR, Southern or western blot to 
check for uptake of the plasmid.  
 
2.7 CELL CULTURE MAINTENANCE 
Each vial of human acute monocytic leukemia cell line THP-1 (ATCC™ TIB-
202™) was thawed at 37 
o
C in a water bath and the cells were washed with RPMI-1640 
medium and resuspended in 20ml RPMI-1640 supplemented with heat inactivated 10% 
fetal calf serum. Cells were grown in a 37 
o
C incubator in the presence of 5% CO2. THP-
1 cells were passaged before their concentration reached 0.8 x 10
6
 cells/ml.    
 
2.8 INFECTIONS 
For infections, 0.6-0.9 million THP-1 cells per ml were plated into 24 well plates 
in the presence of 20ng/ml phorbol 12-myristate 13-acetate and incubated for 20hr. 
Before infection, cells were washed three times with magnesium/calcium-free phosphate 
buffered saline (PBS) and 0.5ml of infection medium (RPMI-1640, 10% heat inactivated 
FCS, 5% human serum) was added to each well. Bacteria to be used in the infections 
were washed once with PBS containing 0.05% Tween®-80 (PBST). A sample of bacteria 
was mixed in equal ratio with 10% formalin in a cuvette and the OD was measured. Cells 
were infected at a multiplicity of infection (MOI) of 3:1 by adding three times the amount 
of bacteria per cell and incubating the plates for 4hr at 37 
o
C in the presence of 5% CO2. 
Infection media was removed after 4hr and the wells were washed two times with PBS 
and then 1ml chase medium (RPMI-1640, 10% heat inactivated FCS, 100µg/ml 
gentamicin) was added to each well. Cells were then incubated for the indicated times. At 
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the end of infections, the chase media in the wells were placed in 15ml tubes and PBS 
with 5mM ethylenediaminetetraacetic acid (EDTA) was added to the wells to lift the 
cells. The lifted cells were added to the 15ml tubes and centrifuged. The cell pellets were 
resuspended in 4% paraformaldehyde overnight at 4
o
C to fix cells and kill intracellular 
Mtb. For infections on slides, 120,000 cells were plated into each well of 3-well slides 
and incubated as mentioned before. When glutathione, N-acetyl cysteine, diphenylene 
iodonium were used they were included both in the infection and the chase media. 
 
2.9 DETECTION OF APOPTOSIS 
To detect apoptosis in THP-1 cells, the In Situ Cell Death Detection Kit, 
Fluorescein was used. This kit labels the free 3’-OH termini of DNA with fluorescein-
dUTP using the enzyme terminal deoxynucleotidyl transferase (TdT). The reaction is 
called TdT-mediated dUTP-X nick end labeling (TUNEL). Before TUNEL, cells were 
washed two times with PBS and permeabilized with permeabilization solution that 
contained 0.1% Triton® X-100 and 0.1% sodium citrate on ice for 3 min. Cells in each 
sample were incubated with 50µl TUNEL solution that is a mix of the enzyme, 
nucleotides and the buffer. After 1hr at 37 
o
C the cells were washed two times and 
resuspended in PBS. Flow Cytometric analysis of cells was done using either a Becton 
Dickinson FACSCalibur™, FacsCanto™ II, FacsAria™ or Accuri® C6. For measuring 
apoptosis of cells on slides, after the last wash of the cells, wells were left to dry, 
ProLong® Gold antifade reagent with DAPI was added to the wells and coverslips were 
placed. Slides were left overnight at room temperature and images of cells were taken 
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using a Zeiss LSM 710 laser scanning microscope and processed using AxioVision LE 
software. 
 
2.10 DETERMINATION OF NECROTIC CELL DEATH 
 To quantify the levels of necrosis in infected cells, ToxiLight
®
 BioAssay Kit 
(Lonza, Rockland, ME) was used. Briefly, 20 µl of cell supernatant from each well was 
added to the wells of a white bioluminescence compatible 96 plate in triplicate and mixed 
with 100 µl of Adenylate Kinase detection reagent (reconstituted in assay buffer). After 5 
min of incubation the luminescence was measured by a BioTek
®
 Synergy microplate 
reader.  
 
2.11 DETERMINATION OF THE NUMBER OF LIVE BACTERIA AFTER 
INFECTION 
To determine the effect of apoptosis on the intracellular growth of Mtb, 
∆Rv3165c, and ∆Rv3167c, for each time point 3 wells of differentiated THP-1 
macrophages were infected with those strains. Following infection, THP-1 cells were 
lysed at 0 hr, 1 day and 2 day time points for 3:1 MOI infections and 0 hr, 1 day, 2 day, 3 
day, 4 day and 6 day time points for 0.5:1 MOI infections using 0.1% Triton X-100 in 
PBS. No gentamicin was used in the chase media in order to keep any extracellular 













 times after 3 day. 
10µl from each dilution was spotted three times on square 7H10 plates. That resulted in 9 
spots for each well of infection. After 14 days the numbers of colonies in the spots were 
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counted and all of the 27 counts for the 3 wells were averaged (The numbers were less in 
case of contaminations or mixing of spots). 
 
2.12 MYCOBACTERIA GENOMIC DNA ISOLATION 
Bacteria (10ml) were centrifuged at 2000 g for 10 min and resuspended in 1ml 
lysis buffer (25mM Tris-HCl, 10mM EDTA, 50mM glucose) and centrifuged again. The 
pellet was resuspended in 450µl lysis buffer. Lysozyme (50µl, 10mg/ml) was added, 
mixed gently and the sample was incubated at 37 
o
C overnight. Sodium dodecyl sulfate 
(100µl) and proteinase K (50µl, 10mg/ml) were added to the sample, mixed and 
incubated at 55
o
C for 30 min. NaCl (200µl, 5M) was added to the sample followed by 
160µl 65 
o
C preheated CTAB (Cetrimide saline solution: 0.1g/ml cetrimide, 0.04g/ml 
NaCl). The sample was incubated at 65
o
C for 10 min. An equal volume (~ 1ml) 
chloroform-isoamyl alcohol (24:1) was added to the sample, mixed gently and the sample 
was centrifuged at 12,000 g for 5 min. The aqueous phase was placed in a new tube and 
mixed with 0.7X volume isopropanol and mixed gently. The sample was incubated at 
room temperature for 5-10 min and centrifuged at 16,000 g for 10 min. The pellet was 
washed with 1ml 70% ethanol, centrifuged at 16.000g for 5 min and air dried. The pellet 
was resuspended in 50µl water. 
 
2.13 SOUTHERN BLOTTING  
The probe DNA for southern blots of Rv3165c was made by PCR using the 
primers that were used to amplify the 5’ end of Rv3165c for knockout production. The 
probe DNA for southern blots of Rv3167c was made by PCR using the primers that were 
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used to amplify the 3’ end of Rv3167c for knockout production. The probes were labeled 
with biotin using BrightStar® Psoralen-Biotin Kit. Genomic DNA isolated from the 
clones was digested with XhoI for Rv3165c southern blots and with EcoRI for Rv3167c 
southern blots. The DNA fragments were separated by agarose gel electrophoresis, 
transferred to charged nylon membrane, and denatured with 0.4N NaOH. The probe was 
denatured at 90 
o
C for 10 min in the presence of 10mM EDTA and hybridized to the 
membrane at 55 
o
C for 16 hr in hybridization buffer (AlkPhos Direct™ hybridization 
buffer with 0.5M NaCl). The membrane was washed and the probe was detected using a 
BrightStar® BioDetect™ Nonisotopic Detection Kit. 
 
2.14 CASPASE ACTIVITY DETECTION 
Caspase activity was detected by Fluorescent-Labeled Inhibitor of Caspases 
(FLICA™). A working solution of the FLICA™ reagent was added to the cells and 
incubated for 1hr at 37 
o
C. Cells were washed two times and resuspended with PBS. 
Analysis was accomplished using flow cytometry. 
 
2.15 WHOLE CELL LYSATE PREPARATION 
Cells were lysed using lysis buffer (for mycobacteria: 50mM Tris-HCl [pH 7.5], 
5mM EDTA, 0.6% SDS, 10mM Na3PO4, prokaryotic protease inhibitor cocktail; for 
THP-1 cells 50mM Tris-HCl, 150mM NaCl, 1% Triton® X-100, eukaryotic protease 
inhibitor cocktail). To lyse mycobacteria, glass beads were added to the tubes and the 
cells were lysed for 10 min using a Biospec Mini-Beadbeater-8. Samples were 
centrifuged at 10,000g for 5 min at 4 
o
C and the supernatants were filtered through 
 43 
Costar® Spin-X® centrifuge tube filters to remove whole bacteria. Thermo Scientific 
Pierce BCA Protein Assay Kit was used to determine protein concentrations (156). 
 
2.16 POLYACRYLAMIDE GEL ELECTROPHORESIS AND WESTERN 
BLOTTING 
Sample protein (≤ 50 µg) was mixed with sample buffer (250mM Tris-HCl, pH 
6.8, 8% SDS, 40% glycerol, 10% β-mercaptoethanol and 0.01% bromophenol blue) at a 
4:1 ratio and proteins were denatured at 95 
o
C for 5 min and placed on ice (155). Samples 
were pipetted into the wells of 4-20% polyacrylamide gradient gels and separated at 
125V using Tris-HEPES-SDS running buffer (Thermo Scientific). Proteins were 
transferred to a 0.45µm PVDF membrane using Genie® Blotter (Idea Scientific). 
Membranes were blocked using 5% non-fat dry milk in PBS for 1hr at room temperature 
and incubated with primary antibodies diluted in the recommended buffer. After 
secondary antibody incubation, the chemiluminescent signal was produced using 
SuperSignal West Pico Chemiluminescent Substrate or SuperSignal West Femto 
Substrate. 
 
2.17 SUBCELLULAR FRACTIONATION 
For each fractionation, 50ml cells were centrifuged at 3000g for 15 min. The 
pellets were washed with PBS, centrifuged again and resuspended in breaking buffer 
(PBS, 1% protease inhibitor cocktail, 20 µg/ml soybean trypsin inhibitor, 25µg/ml 
DNase, 50µg/ml RNase). Cells were lysed using a French® Press. Unbroken cells were 
pelleted at 3000g for 20 min. The supernatants were centrifuged at 100,000g for 2hr to 
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pellet the cell wall and the cell membrane (cell envelope). The supernatants that 
contained cellular cytoplasm were transferred to fresh tubes and the pellets were washed 
with PBS. The pellets were resuspended in the breaking buffer without DNase and 
RNase.  
 
2.18 CULTURE FILTRATE PREPARATION 
To prepare culture filtrates (CF), bacteria were grown in 7H9 medium and 
passaged three times in Sauton’s liquid medium (155), centrifuged and the supernatant 
was filtered (0.22µm). CFs were concentrated at least 20 times using Centriplus® YM-3 
centrifugal filters. Protease inhibitor cocktail (1% final concentration) and soybean 
trypsin inhibitor (20 µg/ml final concentration) were added to the CFs. 
 
2.19 RNA ISOLATION 
Cells were lysed using TRIZOL® Reagent and pipetting. To lyse mycobacteria, 
200µl zirconia beads were added to the tubes and the cells were lysed using Biospec 
Mini-Beadbeater-8. After 5 min at room temperature, chloroform (0.2 volume) was added 
to the samples and the samples were shaken vigorously for 20 sec and incubated at room 
temperature for 3 min. Samples were centrifuged for 15 min at 12,000 g at 4 
o
C and the 
aqueous phase was transferred to a new tube. The chloroform extraction was repeated and 
the final aqueous phase was mixed with an equal volume of isopropanol. After the 
samples were gently mixed, they were incubated at room temperature for 10 min and 
spun for 10 min at 12,000 g at 4 
o
C. The pellets were washed with 70% ethanol, air dried 
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and resuspended in RNase free water. TURBO DNA-free™ was added to RNA samples 
to degrade DNA.     
 
2.20 REVERSE TRANSCRIPTION AND REAL-TIME QUANTITATIVE 
POLYMERASE CHAIN REACTION (RT-QPCR) 
cDNA was produced from RNA using the Thermo Scientific Phusion® RT-PCR 
Kit. For each reaction, cDNA was produced from 500ng RNA using random hexamers. 
Triplicates were processed for qPCR using a LightCycler® 480 SYBR Green I Master kit 
and the Bio-Rad CFX96™ real-time PCR machine. qPCR reactions included 0.5µM of 
each primer and 0.5µl cDNA.  
 
2.21 SAMPLE PREPARATION FOR RNA SEQUENCING 
Ribosomal RNA (rRNA) was removed from 5µg RNA samples using Ribo-
zero™ kits. To remove bacterial rRNA from infected THP-1 RNA samples Gram(+) 
Bacterial Ribosomal Removal Solution was included in the reactions. ScriptSeq™ 
mRNA-Seq Library Preperation kit was used to prepare a RNA sequencing library from 
these rRNA depleted RNA samples.  
 
2.22 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) 
CCL3 and CCL20 concentrations in the cell culture supernatants were measured 
using DuoSet ELISA kits. Briefly, 96-well plates were coated with 2µg/ml (CCL3) or 
0.4µg/ml (CCL20) capture antibody. After 16 hr incubation, wells were washed three 
times with 400µl PBST and blocked with 300µl reagent diluent (1% BSA in PBS) for 1hr 
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at room temperature. Wells were washed and 100µl of triplicates of sample or standards 
were added to the wells. After 2hrs at room temperature, wells were washed and 100µl 
detection antibody (36µg/ml) in reagent diluent was added to the wells for 2hrs at room 
temperature. Wells were washed and 100µl 1X Streptavidin-AP was added to the wells 
for 20 min at room temperature. Wells were washed and 100µl substrate solution 
(1mg/ml p-nitrophenyl phosphate disodium salt dissolved in 1.02M diethanolamine, pH 
9.8) was added to the wells. The absorbance of samples at 405 nm was measured after 5-
10 min. 
 
2.23 MEASUREMENT OF HUMAN INFLAMMATORY CYTOKINE LEVELS IN 
SUPERNATANTS USING A CYTOMETRIC BEAD ARRAY KIT 
BD Cytometric Bead Array (CBA) Human Inflammatory Cytokines Kits were 
used for measuring the levels of IL-8, IL-1β, IL-6, IL-10, TNF-α and IL-12p70 cytokines 
in the supernatants 48 hr after infection. 50µl mixed capture beads were mixed with 50µl 
PE detection reagent and with either 50µl standards or samples. After 3 hr at room 
temperature, 1ml wash buffer was added and samples were centrifuged. The pellets were 
resuspended in 300µl wash buffer and samples were analyzed using a flow cytometer.  
 
2.24 INFECTION OF SCID MICE AND DETERMINATION OF THE 
BACTERIAL LOAD 
To infect the mice with mycobacteria, 7 mice were placed in the basket of the 
Glas-Col
®
 Inhalation Exposure System (Model No A 4212), the lid was closed and 
clamped. A sterile nebulizer was attached to the machine. 5x10
6
 wild type Mtb in 5ml 
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PBST was injected into the nebulizer with a syringe. A standard program was employed: 
1800 seconds nebulizing time, 1800 seconds cloud decay time, 900 seconds 
decontamination time. After the UV lights turned off, the mice were removed and placed 
into their cages. The nebulizer was placed into a solution of vesphene for sterilization. 
The basket and the inside of the machine were cleaned with vesphene and 70% ethanol. 
A new sterile nebulizer was attached to the machine to infect the mice with ∆3167c and 
the same protocol was followed. 
To determine the bacterial load, three mice per condition were sacrificed the next 
day. Mice were sedated by placing cotton balls that had 1ml isoflurane into the containers 
and then killed via cervical dislocation. The thoracic cavity was opened and the lungs 
were removed. A small piece of the left lung was cut and placed in 10% buffered 
formalin for histopathology. The rest of the lung was cut into very small pieces with 
scissors. The pieces were placed in a Stomacher
®
 bag and 4.5ml PBST was added. The 
bag was sealed and placed in another bag. The bag was then placed in a Stomacher
® 
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Biomaster for mashing the lung pieces for 5 min on high setting. The homogenate was 
filtered through a strainer into a 50ml tube. The bacteria were pelleted by centrifuging for 
15 min at 2000g. The pellets were resuspended in 200µl PBST and plated on 7H10 
plates. The plates were checked for colonies after 3-4 weeks of incubation at 37 
o
C. The 
numbers of colonies were counted and the numbers were graphed. Mice were observed 
daily and disease progression was scored as agreed by the University of Maryland 
Institutional Animal Care and Use Committee (IACUC) until they were in a moribund 
state and had to be sacrificed.  
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2.25 STATISTICAL ANALYSIS 
 Unless otherwise noted, one way analysis of variance (ANOVA) with Tukey post-
test was performed using GraphPad Prism
®
 5 to find the significance of difference 
between the data values. The graph bars show the mean of the data while the error bars 
show the standard deviation. Significance is shown as: ns, not significant; *, 0.01< p 



















CHAPTER 3 RESULTS 
3.1 RV3165C AND RV3167C ARE ANTI-APOPTOTIC GENES 
3.1.1 ∆Rv3165c and ∆Rv3167c induce high levels of apoptosis of THP-1 
macrophages 
The 7/10 region of the J21 cosmid was shown to contain anti-apoptotic genes of 
Mtb (Velmurugan, K. unpublished) (Figure 7). Dr. Jessica Miller created single gene 
deletions of the genes in this region in Mtb H37Rv (∆MoxR3, ∆Rv3165c, ∆Rv3166c, 
∆Rv3167c) and her preliminary experiments suggested that Rv3165c and Rv3167c were 
the anti-apoptotic genes in the 7/10 region. In order to confirm this, Mtb with single gene 
deletions (∆MoxR3, ∆Rv3165c, ∆Rv3166c, and ∆Rv3167c) were used to infect PMA-
differentiated THP-1 macrophages. THP-1 cells were incubated 4 days after infection and 
the percentage of apoptotic cells was determined with the TUNEL assay. ∆Rv3165c and 
∆Rv3167c induced significantly higher levels of apoptosis (36.36% and 43.73%) 
compared to Mtb (11.81%), while other deletions (∆MoxR3 [14.20%] and ∆3166c 
[16.53%]) did not (Figure 10). Thus, it was confirmed that the ∆Rv3165c and ∆Rv3167 
strains that were used in the infection experiments are pro-apoptotic. 
 
3.1.2 ∆Rv3165c and ∆Rv3167c are confirmed to be knock-outs for Rv3165c and 
Rv3167c  
To confirm that ∆Rv3165c and ∆Rv3167c were knockouts, genomic DNA was 
isolated from the bacterial cultures and used in PCRs that amplify a 150 bp region in the 
middle of the genes. Separation of PCR products on an agarose gel confirmed the lack of 














Figure 10: ∆Rv3165c and ∆Rv3167c induce significantly more apoptosis of THP-1 
macrophages. PMA-differentiated THP-1 macrophages were untreated (UT) or infected 
with Mtb or the knock-out strains for 4 days. The cells were collected and stained with 
TUNEL to determine the % of apoptotic cells. Data are the mean ± SEM of three 
independent experiments performed in duplicate (n=6). Statistical significance was 
determined by one way analysis of variance (ANOVA) with Tukey post-test: ns, not 








































(Figure 11). Genomic DNA was also digested with restriction enzymes to give different 
sizes of DNA fragments around the genes. Southern blots were performed to show the 
size difference of the bands that hybridized to the probes. Wild type Mtb should give a 
band of 2003bp with the probe after XhoI digestion of its genomic DNA, while 
∆Rv3165c should give a 6422bp band (Figure 12A). Wild type Mtb should give a band of 
6045bp with the probe after EcoRI digestion of its genomic DNA, while ∆Rv3167c 
should give a 2620bp band (Figure 12C). Southern blots confirmed the insertion of the 
hygromycin fragment inside the genes in the knock-out bacteria (Figure 12B, 12D). 
These experiments confirmed the lack of Rv3165c in ∆Rv3165c strain and lack of 
Rv3167c in ∆Rv3167c strain.   
 
3.1.3 ∆Rv3165c and ∆Rv3167c complementation reverses their pro-apoptotic 
phenotypes 
To show that the pro-apoptotic phenotype of ∆Rv3165c and ∆Rv3167c resulted 
from the lack of the genes and no other additional genetic mutation or epigenetic factor, 
the knockouts were complemented by reintroducing the knocked-out gene. Following the 
complementations the bacteria were used to infect PMA-differentiated THP-1 cells for 2 
days. Both knockouts were complemented as the 65.18% apoptosis rate induced by 
∆Rv3165c went down to 19.85% which is not significantly different than the 10.49% 
induced by Mtb (Figure 13A). Similarly, the 83.41% apoptosis rate induced by ∆Rv3167c 
went down to 8.75% which is not significantly different from the 15.75% induced by Mtb 
(Figure 13B). The difference in the apoptosis of THP-1 macrophages infected by 
∆Rv3165c and ∆Rv3167c in the screening of 7/10 region (Figure 10) versus the later  
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Figure 11: Confirmation of deletion of Rv3165c and Rv3167c by RT-PCR. cDNA 
was synthesized from RNA samples isolated from wild-type Mtb and the knock-out 
strains. Primers amplifying 235 and 281 bp regions in the middle of Rv3165c and 
Rv3167c respectively were used in PCR reactions.  
 
1: No cDNA control 
2: Mtb RNA 
3: ∆Rv3165c RNA 
4: ∆Rv3167c RNA 
5: Mtb cDNA 
6: ∆Rv3165c cDNA 
7: ∆Rv3167c cDNA 
8: 100 bp DNA ladder 
9: No cDNA control 
10: Mtb cDNA 
11: ∆Rv3165c cDNA 
12: ∆Rv3167c cDNA 
13: No cDNA control 
14: Mtb cDNA 
15: ∆Rv3165c cDNA 

























Figure 12: Confirmation of the insertion of the hygromycin resistance gene into the 
Rv3165c and Rv3167c genes. The theoretical sizes of fragments that would be detected 
with the probes after digestion of Mtb and ∆Rv3165c genomic DNA with XhoI (A) or 
digestion of Mtb and ∆Rv3167c genomic DNA with EcoRI (C). Arrows represent the 
genes, green regions inserted in the genes represent hygromycin genes. Southern 
































EcoRI EcoRI EcoRI 
 54 










Figure 13: Complementation of ∆Rv3165c and ∆Rv3167c reverses their pro-
apoptotic phenotypes. THP-1 cells were infected with Mtb, ∆Rv3165c and its 
complement or with ∆Rv3167c and its complement for 2 days. The cells were collected 
and stained with TUNEL to determine the % of apoptotic cells. Data are the mean ± SEM 
of three independent experiments performed in duplicate (n=6). Statistical significance 
was determined by one way analysis of variance (ANOVA) with Tukey post-test: ns, not 

































































experiments (Figure 13) is attributed to the use of different stocks of THP-1 cells and/or 
batches of heat inactivated fetal calf serum. Although in the later experiments infected 
cells go through higher rates of apoptosis in a shorter amount of time, this phenotype has 
stayed consistent for all of the experiments.  
To confirm that ∆Rv3165c::C and ∆Rv3167c::C were complements, genomic 
DNA was isolated from the bacterial cultures and digested with restriction enzymes to 
give different size fragments of DNA around the genes. Southern blots were performed to 
show the size differences of the bands hybridized to the probes. Southerns confirmed the 
presence of an extra band from the complementation plasmid in the complements (Figure 
14, 15). Thus, it was confirmed that ∆Rv3165c::C and ∆Rv3167c::C were complements 
and that through complementation the pro-apoptotic phenotypes of ∆Rv3165c and 
∆Rv3167c were reversed. It was also confirmed that the pro-apoptotic phenotypes of 
∆Rv3165c and ∆Rv3167c were due to lack of Rv3165c and Rv3167c respectively. 
 
3.1.4 Apoptosis of infected cells inhibits the intracellular growth of ∆Rv3167c 
Apoptosis of infected macrophages reduces the number of phagocytosed 
mycobacteria (135, 157). To determine the effect of apoptosis on the intracellular growth 
of ∆Rv3165c and ∆Rv3167c, THP-1 macrophages were infected with Mtb, ∆Rv3165c 
and ∆Rv3167c at an MOI of 3:1. Infected THP-1 cells were lysed right after infection, 
and 1 day and 2 days post infection, and the numbers of live intracellular bacteria were 
determined. No significant differences were observed between Mtb and the knockout 
strains for the three time points (Figure 16A). In order to find if there were live 
extracellular mycobacteria in the chase media and if their number would make a  
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Figure 14: Confirmation of complementation of ∆Rv3165c by southern blot. The 
theoretical sizes of fragments that would be detected with the probes after digestion of 
Mtb, ∆Rv3165c and ∆Rv3165c::C genomic DNAs with XhoI (A). Southern experiment 
showed the presence of the expected extra band in the complement of ∆Rv3165c (B). The 











































Figure 15: Confirmation of complementation of ∆Rv3167c by southern blot. The 
theoretical sizes of fragments that would be detected with the probes after digestion of 
Mtb, ∆Rv3167c and ∆Rv3167c::C genomic DNAs with EcoRI (A). Southern experiment 
showed the presence of the expected extra band in the complement of ∆Rv3167c (B). The 








































Figure 16: Apoptosis inhibits growth of ∆Rv3167c inside macrophages. THP-1 
macrophages were infected with Mtb or ∆Rv3165c or ∆Rv3167c at an MOI of 3:1 with 
(A) or without (B) gentamicin in the chase media (3 wells per condition). Cells were 
lysed right after 4 hr of infection (0 day), 1 and 2 day after infection. Dilutions were 
made and spotted on 7H10 plates. Numbers of colonies were counted 14 days after 
incubation at 37
o
C. Data are the mean ± SEM of two independent experiments performed 
in triplicates (n=6). Statistical significance was determined by one way analysis of 
variance (ANOVA) with Tukey post-test. *, 0.05< p <0.01. See materials and methods 















































difference in the total number of live mycobacteria, gentamicin was omitted in the chase 
media. When gentamicin was omitted from the chase media and the experiment was 
repeated for ∆Rv3167c the number of ∆Rv3167c was 30% less than the number of Mtb 2 
day post infection indicating that the difference is due to the extracellular mycobacteria 
(Figure 16B). From there on no gentamicin was used in the chase media for those 
infections.  The presence of gentamicin-sensitive mycobacteria suggests that some of the 
intracellular mycobacteria that were released via apoptosis got out of the apoptotic bodies 
and/or some of the intracellular mycobacteria got out of the cells via other ways (158, 
159). When the infections were done with an MOI of 0.5:1 no significant difference was 
observed between Mtb and ∆Rv3167c for the three time points (Figure 17A). However 
when the numbers of bacteria were determined 6 day post infection the number of 
∆Rv3167c was 56% less than the number of Mtb, showing that apoptosis of ∆Rv3167c 
infected cells inhibited the growth of ∆Rv3167c while Mtb continued to grow (Figure 
17B). A preliminary experiment performed with ∆Rv3167c::C in addition to Mtb and 
∆Rv3167c did not reveal any significant difference between the numbers of bacteria up to 
3 day post infection but the experiment has to be repeated with further time points to be 
comparable to the previous experiments (Figure 17C). In order to find the rate of necrosis 
of THP-1 macrophages infected with Mtb and ∆Rv3167c and confirm that it is apoptosis 
that inhibits the growth of ∆Rv3167c in infected cells, the release of intracellular 
adenylate kinase (AK) into cell culture supernatant was measured by means of the 
ToxiLight
®
 bioluminescence Assay 2 day post infection (Figure 18). At an MOI of 3:1, 
cells infected with ∆Rv3167c were significantly less necrotic (12%) compared to cells 
infected with Mtb (25.6%). At an MOI of 0.5:1, cells infected with ∆Rv3167c were not   
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Figure 17: Apoptosis inhibits growth of ∆Rv3167c inside macrophages. THP-1 
macrophages were infected with Mtb or ∆Rv3167c or ∆Rv3167c::C at an MOI of 0.5:1 (3 
wells per condition). Cells were lysed right after 4hr of infection (0 day) and 2 day after 
infection (A) or 0 day, 2 day, 4 day and 6 day after infection (B) or 0 day, 1 day, 2 day 
and 3 day after infection (C). Dilutions were made and spotted on 7H10 plates. Numbers 
of colonies were counted 14 days after incubation at 37
o
C. Data are the mean ± SEM of 
two independent experiments performed in triplicate (n=6) (A and B) or the mean ± SEM 
of one experiment performed in triplicate (n=3) (C). Statistical significance was 
determined by one way analysis of variance (ANOVA) with Tukey post-test. ***, 
0.0001< p < 0.001. See materials and methods for a detailed protocol.  




































































Figure 18: A low percentage of ∆Rv3167c infected THP-1 cells go through necrosis. 
AK release assay was performed 2 day post infection of THP-1 macrophages at MOIs of 
3:1 and 0.5:1. Staurosporine was added to the cells as positive control. Data are means of 
triplicates of one representative experiment (n=3). Error bars represent SEM. Statistical 
significance was determined by one way analysis of variance (ANOVA) with Tukey 





































more necrotic (0.8%) compared to cells infected with Mtb (2.3%). The significantly 
higher rate of necrosis for Mtb at MOI of 3:1 but not at 0.5:1 suggests that Mtb induces 
necrosis at higher MOIs. These results also suggest that the increased numbers of Mtb 
seen 2 day post infection following 3:1 MOI infection is due to Mtb replicating inside 
THP-1 cells, causing necrosis and getting out of the cell. The experiments with 
gentamicin strengthen this idea since the presence of gentamicin kills extracellular 
bacteria and neither an increase in numbers of Mtb nor a difference compared to 
∆Rv3167c were seen (Figure 16A).  
 
3.2 ANALYSIS OF EFFECTS OF ∆RV3165C OR ∆RV3167C INFECTION ON 
THE HOST CELLS 
 
3.2.1 ∆Rv3165c and ∆Rv3167c induce high levels of caspase-3 and/or 7 and 8 
activities in THP-1 cells 
 Apoptosis of macrophages infected with mycobacteria is mediated by the effector 
caspases 3 and 7 (79, 160, 161). In order to find if caspases are involved in the pro-
apoptotic phenotype of ∆Rv3165c and ∆Rv3167c in 24hr infected cells, cells were stained 
with FLICA™ reagent. FLICA™ reagent consists of a fluorescent dye attached to a 
caspase inhibitor, which is a peptide sequence that binds to caspases. When the FLICA™ 
reagent enters the cell it binds to active caspase and is retained in the cell during the 
washes. The number of cells that contain activated caspase is then determined by flow 
cytometry. When caspase-3 and 7 FLICA™ reagent was used it was found that a higher 
percentage of THP-1 cells infected with ∆Rv3165c or ∆Rv3167c had caspase-3 and/or 7 
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activity (17.21% and 17.89% respectively) compared with Mtb infected cells (8.30%) 
(Figure 19A). Similarly, when caspase-8 FLICA™ reagent was used it was found that a 
higher percentage of THP-1 cells infected with ∆Rv3165c or ∆Rv3167c had caspase-8 
activity (27.29% and 28.45% respectively) compared to Mtb infected cells (11.80% ) 
(Figure 19B). However staining of the 24hr infected THP-1 cells with caspase-9 
FLICA™ reagent showed that a similar percentage of THP-1 cells infected with Mtb, 
∆Rv3165c or ∆Rv3167c had caspase-9 activity (7.84%, 11.1%, 13%) respectively (Figure 
19C). These experiments showed that caspases-3 and/or 7 and 8 were activated in 
∆Rv3165c and ∆Rv3167c infected THP-1 cells and that apoptosis of ∆Rv3165c and 
∆Rv3167c infected cells was likely a result of the extrinsic pathway of caspase activation. 
 
3.2.2 Inhibiting ROS production or scavenging ROS leads to loss of the pro-
apoptotic phenotype of ∆Rv3165c and ∆Rv3167c 
Increased levels of ROS can promote apoptosis by inducing prolonged JNK 
activation and blocking NF-κB activation (115). Previous work in our lab showed that the 
pro-apoptotic phenotype of ∆nuoG was abolished in the presence of ROS inhibitor or 
scavengers and that the phagosomes of cells infected with ∆nuoG had higher levels of 
ROS (149). Therefore, in order to investigate the involvement of host cell produced ROS 
in the apoptosis of ∆Rv3165c and ∆Rv3167c infected cells, ROS production was blocked 
by NADPH oxidase inhibitor diphenylene iodonium (DPI). Alternatively ROS 
scavengers were added to the infection and chase media to block the effects of ROS. 
Blocking ROS production by DPI led to loss of the pro-apoptotic phenotypes of 


















































Figure 19: ∆Rv3165c and ∆Rv3167c induce significantly higher levels of caspase-3 
and/or 7 and 8 but not caspase-9 activity in THP-1 cells. Caspase activities were 
detected by staining cells 24hr after infection with the FLICA™ reagent. For + control 
staurosporine (1µM) was added to uninfected cells. Data are the mean ± SEM of two 
independent experiments performed in duplicate (n=4). Statistical significance was 
determined by one way analysis of variance (ANOVA) with Tukey post-test. ns, not 




































































∆Rv3167c infected cells was reduced to 15.98% and 17.76% respectively compared to 
13.63% apoptosis in Mtb infected cells (Figure 20A). Addition of glutathione to the 
media led to a decrease of apoptosis from 24.13% and 18.48% for ∆Rv3165c and 
∆Rv3167c infected cells to 1.05% and 0.51% respectively. Addition of NAC decreased 
the apoptosis levels to 1.03% and 1.84% (Figure 20B). Removal of ROS by these two 
methods and the loss of the pro-apoptotic phenotype of the knock-outs showed the 
involvement of ROS in the apoptosis of infected cells. 
 
3.2.3 Secreted cytokine profile of cells infected with Mtb versus ∆Rv3167c or 
∆Rv3167c::C 
To identify any possible differences in the levels of IL-8, IL-1β, IL-6, IL-10, 
TNF-α and IL-12p70 after infection in the supernatants of THP-1 macrophages, the BD 
Cytometric Bead Array (CBA) Human Inflammatory Cytokines Kit was used. This kit 
was chosen as it could detect Th1 cytokines IL-12 and TNF-α, pro-inflammatry cytokines 
IL-1β and IL-6, and IL-10, which down regulates Th1 responses. No significant 
difference was found in the levels of these cytokines in the supernatants of THP-1 
macrophages infected for 2 days with Mtb, ∆Rv3167c or ∆Rv3167c::C (Figure  
21). ∆Rv3167c and its complement were chosen in this experiment due to sample 
limitations of the kit. However, in some of the following experiments Rv3165c was 
 omitted due to the complexity and hardship of working with two strains compared to 
one. The lack of difference in the levels of cytokines tested indicates that the pro-
apoptotic phenotype of ∆Rv3167c is not due to an increase or decrease in the secretion of 


















Figure 20: Inhibiting ROS production of scavenging ROS abolishes apoptosis 
induction by ∆Rv3165c and ∆Rv3167c. Infected THP-1 cells were incubated with DPI 
(A) or Glutathione or NAC (B) and were collected 2 days (A) or 36hrs (B) after infection 
and stained with TUNEL to determine the % of apoptotic cells Data are the mean ± SEM 
of two independent experiments performed in duplicate (n=4) (A) or the mean ± SEM of 
a representative experiment with four replicates per group (n=4) (B). Statistical 
significance was determined by one way analysis of variance (ANOVA) with Tukey 



























































+ Glutathione + NAC
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Figure 21: Detection of the amounts of cytokines in the supernatants of uninfected 
or Mtb or ∆Rv3167c or ∆Rv3167c::C infected THP-1 macrophages. A BD CBA kit 
was used to measure the amounts of IL-8 (A), IL-1β (B), IL-6 (C), IL-10 (D), TNF-α (E) 
and IL-12 p70 in the supernatants of uninfected THP-1 macrophages or THP-1 
macrophages infected with Mtb or ∆Rv3167c or ∆Rv3167c::C. Data are the mean ± SEM 
of two independent experiments performed in duplicate (n=4). Statistical significance 
was determined by one way analysis of variance (ANOVA) with Tukey post-test versus 
Mtb. ns, not significant. 








































































































3.2.4 Deletion of Rv3167c changes the expression of host genes in vivo 
In order to better understand how ∆Rv3167c induces apoptosis of THP-1 
macrophages, the host gene expression profile was determined by RNA sequencing. 
RNA was isolated from uninfected THP-1 macrophages and from those that were 
infected with Mtb or ∆Rv3167c for 16hr. rRNA was removed from the total RNA 
samples and a RNA sequencing library was prepared. Sequencing of this library showed 
that there were 2332 differentially regulated genes in THP-1 macrophages infected with 
Mtb vs. ∆Rv3167c. 1223 genes were upregulated in Mtb infected THP-1 macrophages 
compared to 1109 genes in ∆Rv3167c infected THP-1 macrophages. There were few 
bacterial transcripts that were detected in these samples and comparison of bacterial gene 
expression could not be made. Real time qPCR (RT-qPCR) was used for selected 
transcripts to validate the results of RNA sequencing. CCL20 was chosen as it is 
upregulated in Mtb infected monocytes. In addition, CCL20 downregulates ROS 
production and inhibits apoptosis of monocytes infected with mycobacteria (162). CCL3 
was chosen as it is induced in macrophages after infection with Mtb and inhibits 
intracellular growth of Mtb (163). In addition since both molecules are secreted, ELISA 
could be employed to find their concentrations in the supernatants of infected cells. 
According to RNA sequencing, Mtb infected cells had 10 fold more CCL3 FPKMs 
(fragment per kilobase of transcript per million mapped reads) than untreated cells and 
∆Rv3167c infected cells had 62 fold more (Figure 22A). RT-qPCR result was similar to 
RNA sequencing result for CCL3 expression (CCL3 was 48.85 fold upregulated in Mtb 
infected cells and 316.11 fold upregulated in ∆Rv3167c infected cells) (Figure 22B). 
According to RNA sequencing, Mtb infected cells had 351 fold more CCL20 FPKMs  
 69 















Figure 22: Regulation of CCL3 and CCL20 expression in Mtb and ∆Rv3167c 
infected THP-1 macrophages. CCL3 and CCL20 expression levels were determined in 
Mtb and ∆Rv3167c infected THP-1 macrophages 16 hr after infection by RNA 
sequencing (A and C) or by real-time qPCR (B and D). Plotted values are fold change in 
FPKMs for CCL3 (A) or CCL20 (C) relative to untreated cells. For B and D data are the 
mean ± SEM of one experiment performed in triplicate (n=3) and the results are depicted 
as fold change relative to Mtb infected cells and normalized for expression of the 
housekeeping gene GAPDH. Statistical significance was determined by one way analysis 




























































































































then untreated cells and ∆Rv3167c infected cells had 26 fold more (Figure 22C). RT-
qPCR showed a different trend compared to RNA sequencing result for CCL20 
expression (CCL20 was 32.32 fold upregulated in Mtb infected cells and 104.4 fold 
upregulated in ∆Rv3167c infected cells) (Figure 22D). These results confirmed the 
upregulation of CCL3 following infection with Mtb. 
In order to find which of the results was correct for CCL20 and confirm CCL3  
results at the protein level, ELISA was used to assay for CCL3 and CCL20. ELISA for 
CCL3 showed that there was significantly more CCL3 in the supernatants of ∆Rv3167c 
infected THP-1 macrophages (227 pg/ml) than Mtb infected ones (184 pg/ml) 24 hrs after 
infection. ELISA also showed that 48 hr after infection, there was significantly more 
CCL3 in the supernatants of ∆Rv3167c infected THP-1 macrophages (267 pg/ml) than 
Mtb infected ones (69 pg/ml) (Figure 23A). The decrease in CCL3 levels in untreated and 
Mtb infected cells between 24 and 48 hr is thought to be due to degradation. Cancer cell 
lines are implicated in degradation of CCL3 (164) and THP-1 cell line can also be 
degrading CCL3 in the supernatant. The lack of a decrease for ∆Rv3167c might be due to 
high levels of CCL3 translation in the cells that hides a decrease in CCL3 levels in the 
supernatant. While ELISA confirmed CCL3 expression differences that were seen both in 
RNA sequencing and qPCR, CCL20 protein levels were slightly lower in the 
supernatants of ∆Rv3167c infected THP-1 macrophages (540 pg/ml) than in the 
supernatants of Mtb infected ones (737 pg/ml) 24 hrs after infection and also similar in 
the supernatants of ∆Rv3167c infected THP-1 macrophages (676 pg/ml) compared to the 
supernatants of Mtb infected ones (760 pg/ml) 48 hrs after infection (Figure 23B). 



















Figure 23: ELISA confirms upregulation of CCL3 expression in ∆Rv3167c infected 
THP-1 macrophages. CCL3 and CCL20 protein concentrations in the cell culture 
supernatants were measured using DuoSet ELISA kits. Data are the mean ± SEM of two 
experiments performed in triplicate (n=6). Statistical significance was determined by one 
way analysis of variance (ANOVA) with Tukey post-test versus Mtb. ns, not significant; 











































24 hr 48 hr
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results show that a biological replicate of the RNA sequencing experiment is necessary 
and that the results need to be confirmed by qPCR. Also it is important to show that the 
differences in gene expression lead to differences in protein expression since it is mostly 
the difference in protein levels (or activation or deactivation of proteins) that can make a 
difference in the phenotype.  
 
3.2.5 Deletion of Rv3167c changes the expression of host pro-apoptotic and anti-
apoptotic proteins in vivo 
In order to find if the differences in the gene expression levels led to differences 
in protein expression and phosphorylation, the expression and phosphorylation state of 
some of the host proteins was determined. Whole cell lysates of THP-1 macrophages 
infected with Mtb or ∆Rv3167c were prepared 8 and 24hrs after infection. 100µg of 
samples were sent to Kinexus Bioinformatics Corporation, which used the protein 
samples in antibody microarray experiments. For the antibody microarray, proteins in the 
whole cell lysates were attached to fluorescent dye. Control and treated proteins were 
loaded on the same microarray side by side. After incubation, slides are washed and 
scanned. Analysis of the results showed that 33 proteins were differentially regulated in 
cells infected with Mtb vs. ∆Rv3167c for 8hr (Figure 24A). Twenty four proteins were 
differentially regulated in cells infected with Mtb vs. ∆Rv3167c for 24hr (Figure 24B). 
After 8hrs of infection several pro-apoptotic proteins like ABL1, AIFM1, BID, ASK1, 
and BAK were upregulated in ∆Rv3167c infected THP-1 macrophages. Anti-apoptotic 
proteins like RAF1, MAPKK5, RB1, PPP5C, AKT3, SMAD1 were down regulated in 


























Figure 24: THP-1 macrophage proteins whose expression or phosphorylation have 
changed 8 hrs or 24 hrs after infection with ∆Rv3167c compared to Mtb. 100µg of 
whole cell lysates of THP-1 macrophages infected with Mtb or ∆Rv3167c were prepared 
8 (A) and 24hr (B) after infection and used in antibody microarray experiments. Z scores 
are calculated by subtracting the overall average intensity of all spots within a sample 
from the raw intensity for each spot, and by dividing it by the standard deviations (SD) of 
all of the measured intensities within each sample. Z ratios are further calculated by 
taking the difference between the averages of the observed protein Z scores and dividing 
by the SD of all of the differences for that particular comparison. A Z ratio of ±1.2-1.5 is 
inferred as significant. Pink color indicates upregulation in ∆Rv3167c infected cells, blue 
color indicates downregulation in ∆Rv3167c infected cells. 
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expression of pro-apoptotic proteins like RIPK4, AK2, ASK1 and AIFM1 was up 
regulated in ∆Rv3167c infected THP-1 macrophages. At the same time expression of 
anti-apoptotic proteins like SODD, MKK1 and MLK3 was downregulated in ∆Rv3167c 
infected THP-1 macrophages. 
Activation of ABL1 (Abelson tyrosine-protein kinase 1) leads to JNK and p38 
MAPK activation followed by induction of apoptosis (165). ASK1 (Apoptosis signal 
regulating protein-serine kinase, MAP3K5) activation also induces apoptosis through 
JNK and p38 MAPK (166). ATF2 (Activating transcription factor 2) is a transcriptional 
activator that gets activated by p38 MAPK and induces apoptosis (167, 168). Increased 
expression or phosphorylation of these proteins suggests that the apoptosis of ∆Rv3167c 
infected THP-1 macrophages might be regulated via JNK and/or p38 MAPK. According 
to preliminary experiments, inhibiting p38 MAPK activity reduced the apoptosis levels of 
∆Rv3167c infected human MDM’s to the level of wild-type Mtb infected cells 
(Srinivasan L, unpublished data).  
Some of the proteins that were found to be regulated are involved in caspase-9 
activation. Cleaved BID (BH3-interacting domain death agonist) leads to release of 
cytochrome c from mitochondria and caspase-9 activation (169). BAK (Bcl-2 
homologous antagonist/killer) works against the anti-apoptotic function of BCL2 and 
promotes cytochrome c release and caspase-9 activation (170). Knocking down AKT3 
leads to increased caspase-9 activity and apoptosis (171). In addition, caspase-9 was 
found to be upregulated in the antibody microarray. However, as shown in figure 19 
∆Rv3167c infected cells did not have significantly higher levels of active caspase-9. 
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Therefore, we believe that either these results are false positives or caspase-9 levels go 
down after 8 hr.  
 
3.3 EFFECT OF DELETION OF RV3165C AND RV3167C ON 
MYCOBACTERIAL GENE EXPRESSION 
3.3.1 Rv3165c and Rv3167c are required for the increase of katG expression inside 
host cells 
The involvement ROS in the pro-apoptotic phenotype of the knock-out strains 
suggested that the bacteria might lack mechanisms that are able to counter the effects of 
ROS. Mtb only has one catalase gene (katG) that can neutralize the ROS hydrogen 
peroxide, which led to the idea that katG might be regulated by Rv3165c and/or Rv3167c.  
Rv3167c is a probable transcriptional regulatory protein that might belong to the 
TetR family of transcription factors (TFRs) (44) and this predicted function raised the 
possibility that Rv3167c might regulate the expression of other genes. According to 
InterProScan, a software that can identify protein domains, Rv3167c contains an N-
terminal TetR-type DNA-binding (DNB) helix-turn-helix domain and a C-terminal TetR-
like transcriptional regulator domain that includes ligand-binding and dimerization 
(LBD) domain (Figure 25) (172). Most of the TFRs repress transcription of genes when 
they bind to DNA through their DNB domain. Upon binding of a ligand to their C-
terminal (LBD) domain, TFRs detach from DNA (173). There is evidence that some 
TFRs acting as activators. SczA of Streptococcus pneumoniae is a member of TFRs and 
it is involved in the upregulation of genes associated with Zn
2+
 stress (174).  MdoR of 
Mycobacterium sp. Strain JC1, was shown to be a TetR-like transcriptional activator,  
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which is implicated in the upregulation of genes necessary for the oxidation of methanol 
(175).  
RNA was isolated from Mtb, ∆Rv3165c and ∆Rv3167c grown in vitro to log 
phase. Following reverse transcription, real time qPCR was performed to measure katG 
expression. katG expression levels were similar in ∆Rv3165c (1.31 fold over Mtb) and 
∆Rv3167c (1.18 fold over Mtb) compared to Mtb and the difference was not statistically 
significant (Figure 26A). 
To check for the effect of ROS on katG expression in vitro, xanthine and xanthine 
oxidase were added to Mtb, ∆Rv3165c and ∆Rv3167c in vitro cultures to induce 
hydrogen peroxide formation after they were resuspended in PBS. After 90 min of 
incubation, RNA was isolated from the bacteria. Following reverse transcription, real 
time qPCR was performed to measure katG expression. katG expression was found to 
increase in not only Mtb (23.59 fold over Mtb in vitro) but also in ∆Rv3165c and 
∆Rv3167c (33.88 and 33.96 fold over Mtb in vitro) (Figure 26B). To determine if 
∆Rv3165c and ∆Rv3167c can upregulate katG expression in macrophages as well, THP-1 
cells were infected with Mtb, ∆Rv3165c and ∆Rv3167c for 16hr and RNA was isolated 
from infected cells. Following reverse transcription, real time qPCR was performed to 
measure katG expression. Although in macrophages Mtb upregulated katG expression 
12.25 fold over Mtb in vitro, ∆Rv3165c and ∆Rv3167c upregulated katG 5.62 and 8.44 
fold less than Mtb in macrophages respectively (2.18 and 1.45 fold upregulation over 
Mtb in vitro) (Figure 26C). These results suggest that Mtb requires Rv3165c and Rv3167c 
to upregulate katG expression during infection of macrophages. As katG encodes for 



















Figure 26: ∆Rv3165c and ∆Rv3167c do not upregulate katG expression in 
macrophages. RNA was isolated from untreated in vitro cultures (A) or xanthine and 
xanthine oxidase treated in vitro cultures (B) or THP-1 cells infected with mycobacteria 
for 16 hr (C). cDNA was synthesized from RNA and used in real time qPCR 
experiments. Data are of one representative experiment with three replicates per group 
(n=3). Error bars represent SEM. Results are depicted as fold change relative to Mtb 
under the same conditions and normalized for expression of the housekeeping gene SigA. 
Statistical significance was determined by one way analysis of variance (ANOVA) with 
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infection and lack of upregulation of katG in ∆Rv3165c and ∆Rv3167c can explain 
involvement of ROS in the pro-apoptotic phenotypes of those mutants. 
 
3.3.2 Rv3165c is required for Rv3167c expression inside host cells 
As Rv3167c is predicted to be a probable transcriptional regulatory protein and 
Rv3165c and Rv3167c are close to each other in the Mtb genome, RT-qPCR was 
performed to determine if Rv3165c and Rv3167c regulate each others’ mRNA expression. 
To determine if Rv3165c and Rv3167c exert their anti-apoptotic activity through nuoG, 
its expression was measured as well. The expression of nuoB was determined as a control 
since it is a part of the operon that includes nuoG (147). The lack of Rv3165c or Rv3167c 
did not affect the expression levels of any of the genes investigated in vitro (Figure 27A). 
NuoB and nuoG expression levels were not affected by the lack of Rv3167c in 
macrophages either (Figure 27B). 
Real time qPCR was used to measure the expression of Rv3167c in ∆Rv3165c, 
and Rv3165c in ∆Rv3167c. Rv3165c expression in ∆Rv3167c was 1.17 fold increased 
compared to Mtb in macrophages but that was not a significant difference (Figure 28A). 
While Mtb upregulated Rv3167c expression significantly in macrophages (11.48 fold) 
compared to Mtb grown in 7H9, ∆Rv3165c did not upregulate Rv3167c expression 
significantly in macrophages (1.43 fold over Mtb) (Figure 28B). Therefore, it was 
















Figure 27: Regulation of Rv3165c, Rv3167c, katG, nuoB, nuoG in vitro and in 
macrophages. RNA was isolated from in vitro Mtb, ∆Rv3165c and ∆Rv3167c cultures 
and from THP-1 cells infected with Mtb or ∆Rv3167c for 16 hr. cDNA was synthesized 
from the RNA and used in real time qPCR experiments. Data are the mean ± SEM of 
three (n=9) (A) or two (B) independent experiments performed in triplicate (n=6). 
Statistical significance was determined by one way analysis of variance (ANOVA) with 
Tukey post-test. Results are depicted as fold change relative to Mtb in vitro (A) or 






























































































Figure 28: ∆Rv3165c do not upregulate Rv3167c expression in macrophages. RNA 
was isolated from in vitro Mtb, ∆Rv3165c and ∆Rv3167c cultures and from THP-1 cells 
infected with these strains for 16 hr. cDNA was synthesized from the RNA and used in 
real time qPCR experiments. Data are of a representative experiment (out of 3) with three 
replicates per group (n=3). Error bars represent SEM. Results are depicted as fold change 
relative to Mtb in macrophages (A) or Mtb in vitro and normalized for expression of the 
housekeeping gene SigA. Statistical significance was determined by one way analysis of 

















































































3.4 ANALYSIS OF CELLULAR LOCALIZATIONS OF RV3165C AND RV3167C 
To obtain information about the cellular localizations and better understand the 
functions of Rv3165c and Rv3167c, myc-tagged Rv3165c and Rv3167c were expressed 
in BCG. Subcellular fractions were prepared and the distributions of the myc-tagged 
proteins in those fractions were analyzed. Additionally possible presence of the myc- 
tagged proteins in the culture filtrates was investigated.    
 
3.4.1 Rv3165c is in the cell envelope, whereas Rv3167c is in the cytoplasm 
TMHMM Server v. 2.0 (software for prediction of transmembrane helices in 
proteins) predicts that Rv3165c is a transmembrane protein (Figure 29A) whereas 
Rv3167c is secreted (176). Rv3165c is a hypothetical unknown protein whereas Rv3167c 
is a probable transcriptional regulatory protein. For Rv3167c to be involved in 
transcriptional regulation it must be in the cytoplasm. To confirm predicted cellular 
localizations, myc-tagged versions of Rv3165c and Rv3167c were produced in BCG 
using the extrachromosomal expression vector pMV261. Subcellular fractions of BCG 
cultures expressing either Rv3165c-myc or Rv3167c-myc were prepared. Equal 
percentages of cell envelope and cell cytoplasm fractions were separated by PAGE and 
proteins were detected by western blotting. Anti-myc antibody was used to detect myc-
tagged proteins. Rv3165c was localized mostly to the cell envelope whereas Rv3167c 
was solely located in the cytoplasm (Figure 29B). This result confirmed the predicted 
locations of the proteins. LAM and DNAK were used as cell fraction markers. Mtb LAM 
is present soely in the cell envelope fraction and DNAK (probable chaperone protein) is 
present solely in the cytosolic fraction.  
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Inside 1-4 aa 
TM helix 5-22 aa 
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Figure 29: Rv3165c is in the cell envelope and Rv3167c is in the cytoplasm. 
Prediction of transmembrane helices of Rv3165c by TMHMM (A). BCG clones 
expressing myc tagged Rv3165c or Rv3167c were grown to late log phase, lysed using a 
French® Press and the cell envelope fraction was separated from the cytosolic fraction. 
Fractions were separated by PAGE for western blotting. Anti-myc antibody was used for 
detection of myc tagged proteins. Anti-LAM and anti-DNAK antibodies were used for 
detection of LAM and DNAK in the fractions (B). BCG clones expressing myc tagged 
Rv3165c or Rv3167c were grown in Sauton’s medium to late log phase, the cells were 
collected and the culture filtrate was concentrated. Equal percentages of the whole cell 
lysate and the culture filtrate fractions were loaded in the gel. Anti-FAP and anti-GroEL 








3.4.2 Rv3165c and Rv3167c are not secreted 
To check if either of the two proteins was secreted, culture filtrates (CF) of BCG 
expressing the myc-tagged proteins were prepared and concentrated. CF samples and 
whole cell lysates (WCL) were separated by PAGE and proteins were detected by 
western blotting. Anti-myc antibody was used to detect myc-tagged proteins. Both of the 
proteins were only detected in the WCL, showing that they were not secreted (Figure 
29C). Anti-FAP antibody was used to show the presence of FAP (fibronectin attachment 
protein) mostly in the CF fraction (some FAP is present in the cell membrane, which is 
why it is detected in the WCL fraction). Anti-GroEL antibody was used to show the 
presence of GroEL (probable chaperone protein) solely in the WCL fraction and that 
there was no cellular death and lysis that would have released proteins to the CF. 
 
3.5 VIRULENCE OF ∆RV3167C KNOCK-OUT STRAIN 
In order to determine whether knocking out Rv3167c in Mtb changed its virulence 
especially because of its increased pro-apoptotic phenotype, eight SCID mice per 
condition were infected with Mtb and ∆Rv3167c via aerosol route. 24hr later three mice 
per condition were sacrificed and the bacteria from their lungs were plated. The levels of 
bacteria in the lungs were similar (264 ± 33 colony forming units of Mtb vs. 297 ± 23 
colony forming units of ∆Rv3167c) (Figure 30A). The remaining infected mice were 
observed and scored until they were in a moribund state and had to be sacrificed (Figure 
30B).  
All of the ∆Rv3167c infected mice died on the 28
th
 day of infection while Mtb 






























Figure 30: ∆Rv3167c is not less virulent than Mtb in mice. 8 SCID mice were aerosol 
infected with a low dose of Mtb or ∆Rv3167c. A) Colony forming units (CFU) in the 
lungs were shown to be not significantly different between Mtb and ∆Rv3167c (3 mice 
per condition were sacrificed. Statistical significance was determined by one way 
analysis of variance (ANOVA) with Tukey post-test). B) The remaining 5 mice per 
condition were monitored. All of the ∆Rv3167c infected mice died on the 28
th
 day of 




 days of infection. Statistical 











































survival curves to be significantly different indicating possibly that ∆Rc3167c is more 
virulent than Mtb. This experiment has to be repeated to confirm this phenotype of 
∆Rv3167c in SCID mice. 
According to a study designed and supervised by our collaborator Dr.Petros C. 
Karakousis at Johns Hopkins University School of Medicine, ∆Rv3167c is not less 
virulent than Mtb in guinea pigs. Guinea pigs were infected with Mtb, ∆Rv3167c, 
∆Rv3167c::C or ∆NuoG strains by aerosol infection at a low-dose and the numbers of 
mycobacteria in the lungs were determined 1, 28 and 56 day post-infection (Figure 31A).  
Although the number of ∆Rv3167c was significantly higher than the number of wild-type 
Mtb by day 28, they were similar by day 56. The body weights of the guinea pigs were 
measured before they were sacrificed and found to be similar for all of the strains at the 
three time points (Figure 31B). The experiment in mice together with the experiment in 
guinea pigs suggest that ∆Rv3167c is not less virulent than wild-type Mtb. 
 
3.6 SUMMARY 
Mtb inhibits apoptosis of infected host cells and this is thought to enable Mtb to 
survive and prevent a successful immune response from the host. I was able to identify 
Rv3165c and Rv3167c as two novel anti-apoptotic genes of Mtb. THP-1 macrophages 
infected with Mtb knock-out strains lacking Rv3165c or Rv3167c (∆Rv3165c, ∆Rv3167c) 
had high levels of apoptosis. Apoptosis depended on caspase-8 and 3 and/or 7, but not on 
caspase-9 in THP-1 macrophages, suggesting the involvement of extrinsic but not 
intrinsic caspase activation. Inhibiting ROS production or scavenging ROS inhibited the 

















Figure 31: ∆Rv3167c is not less virulent than Mtb in guinea pigs. Guinea pigs were 
infected with Mtb, ∆Rv3167c, ∆Rv3167c::C or ∆NuoG (12 guinea pigs per group; n=12) 
by aerosol infection at a low-dose (less than 100 bacteria per guinea pig) and four guinea 
pigs were sacrificed per strain per time point for determination of number of 
mycobacteria in the lungs (A). The body weights of the guinea pigs were measured 
before they were sacrificed (B). Statistical significance was determined by one way 
analysis of variance (ANOVA) with Tukey post-test. *, 0.05< p <0.01. (Experiment 
designed and supervised by our collaborator Dr.Petros C. Karakousis at Johns Hopkins 




































































































the pro-apoptotic cell signaling pathways, but not start them (103). However, the signal 
that activates the extrinsic caspase activation in ∆Rv3165c or ∆Rv3167c infected 
macrophages is not known at this point.  
Preliminary RNA sequencing and antibody microarray experiments identified 
host cell components that may be differentially regulated in ∆Rv3167c infected cells 
compared to Mtb infected cells. Confirmation of these targets will help identify the host 
cell pathways that Mtb manipulates to inhibit host cell apoptosis and qPCR and other 
methods will be used to confirm Mtb genes that are involved in apoptosis inhibition. 
∆Rv3165c and ∆Rv3167c failed to upregulate the expression of the only catalase 
of Mtb, katG. Therefore, this suggests that Mtb may need to upregulate katG expression 
in order to neutralize host cell produced ROS to inhibit apoptosis. However, there is also 
evidence contradicting these results, which is mentioned in the discussion. Rv3165c was 
found to reside mainly in the cell envelope while Rv3167c, which is predicted to be a 
probable transcriptional regulator, was found to be exclusively in the cytosol of 
mycobacteria. Rv3165c was found to be required for upregulation of Rv3167c expression.  
An experiment using SCID mice as well as another one using guinea pigs suggest 
that ∆Rv3167c is not less virulent than wild-type Mtb as predicted. It was expected that 
this pro-apoptotic mutant would be less virulent as it was shown for the other pro-






CHAPTER 4 DISCUSSION 
 
The presented data established the requirement of Rv3165c and Rv3167c for 
apoptosis inhibition by Mtb in THP-1 macrophages. In addition to THP-1 macrophages, 
experiments using human blood monocyte derived macrophages and guinea pig alveolar 
macrophages confirmed the pro-apoptotic phenotype of ∆Rv3165c and ∆Rv3167c 
(Hurley, B. unpublished). The complementation of ∆Rv3167c was done with the myc-
tagged Rv3167c and it is thought that the tag does not affect the structure and function of 
Rv3167c since the N-terminus of TetR-like transcriptional regulators is surface-exposed 
(173). In addition, ∆Rv3167c was successfully complemented and this suggests that myc-
tagged Rv3167c was functional. 
Infection of THP-1 macrophages either at 3:1 or 0.5:1 MOI inhibits growth of 
∆Rv3167c (Figure 16, 17). The difference was observed in 3:1 MOI infection when 
gentamicin was omitted in the chase media, indicating that the difference is due to 
extracellular mycobacteria. From there on no gentamicin was used in the chase media for 
those infections. The increasing trend of the graph for Mtb after day 1 in the absence of 
gentamicin compared to the decreasing trend in the presence of gentamicin suggests that 
there are many extracellular Mtb that got out of the cells alive, presumably via necrosis. 
When the infections were done at an MOI of 0.5:1 no difference in the numbers of 
bacteria were observed up to 4 day after infection. This was expected since the apoptotic 
phenotype is observed around 4-5 day after infection at that MOI. When the infections 
with different MOIs are compared, 0.5:1 MOI infection has higher inhibitory effect on 
the growth of ∆Rv3167c. This is thought to be due to the presence of uninfected 
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bystander macrophages which can take up the apoptotic blebs resulting from the 
apoptosis of infected macrophages and kill the mycobacteria inside better (177). A recent 
study however suggests that the effect of uninfected macrophages was contact 
independent and they produced a soluble molecule that acted on the infected 
macrophages to increase their antibacterial activities (178). 
Apoptosis of infected cells is reported to kill the intracellular mycobacteria (79, 
135) and our data shows that apoptosis prevented ∆Rv3167c from replicating as much as 
Mtb. This suggests that in our infection system, either apoptosis kills ∆Rv3167c less 
effectively than what has been shown before or apoptosis diminishes the replicating niche 
for ∆Rv3167c, thereby prevent ∆Rv3167c from replicating as much as Mtb but it does not 
necessarily kill it. The number of total mycobacteria (live and dead) can de determined 
by microscopy after infection to better analyze the effect of apoptosis on ∆Rv3167c. 
Apoptosis rate was higher in ∆Rv3167c infected cells, whereas the rate of necrosis was 
significantly lower compared to Mtb infected cells. This is consistent with the reports 
suggesting that Mtb uses necrosis to break free from the cell, unharmed and spreads to 
other uninfected cells (66, 67). Although the necrosis rate is high for Mtb infected cells, 
the percentage of viable cells that can accommodate Mtb is higher, which can lead to 
increased numbers of Mtb. The higher numbers of Mtb is also probably due to the ability 
of Mtb to replicate to bigger numbers inside the cell without causing apoptosis compared 
to pro-apoptotic mutants.   
Apoptosis induced by ∆Rv3165c and ∆Rv3167c was found to involve caspases. 
Since only caspase 8 but not caspase 9 activity was increased in the knock-out infected 
cells, the extrinsic pathway of caspase activation was activated. TNF-α, FasL and TRAIL 
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(TNF-related apoptosis-inducing ligand) induce apoptosis through caspase-8 activation 
(87, 179). TNF-α secretion was not affected in the knock-out infected cells but the 
involvement of FasL or TRAIL in caspase-8 activation is unknown at this point.  
The pro-apoptotic phenotype of ∆nuoG is abolished in the presence of ROS 
inhibitor or scavengers and the phagosomes of cells infected with ∆nuoG have higher 
levels of ROS (149). In order to investigate the involvement of ROS in the pro-apoptotic 
phenotype of ∆Rv3165c and ∆Rv3167c, ROS production was inhibited or ROS was 
scavenged. As in the case of ∆nuoG both of these methods abolished the pro-apoptotic 
phenotypes of ∆Rv3165c and ∆Rv3167c. The amounts of apoptosis induced by ∆Rv3165c 
and ∆Rv3167c in the experiments done on the slides were lower since the time point was 
36 hr instead of 48 hr and some of the apoptotic cells were not adherent at the end of 
infection and were washed off. These experiments indirectly showed that there was an 
increase in ROS production in the ∆Rv3165c and ∆Rv3167c infected cells. ROS detection 
reagents will be employed to test for differences in the levels of ROS produced by 
infected cells. This will directly show if ∆Rv3165c and ∆Rv3167c infected cells have 
higher levels of ROS, presumably in the phagosome. The source of ROS can be 
mitochondrial or phagosomal so experiments will be done with PLB XR-CGD cells, a 
cell line that lacks the cybb gene (no Nox2 expression) to find if the source of ROS is 
phagosomal or not (180).  
The expression of 2332 host genes was found to be significantly affected due to 
the lack of Rv3167c in Mtb via RNA sequencing. RT-qPCR and ELISA were performed 
to check the expression of two genes, CCL3 and CCL20. Although the CCL3 result was 
confirmed, RT-qPCR of CCL20 gave the opposite result of RNA sequencing and ELISA 
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of CCL20 gave a result different than RNA sequencing and RT-qPCR. According to 
these results, it is imperative to repeat RNA sequencing and confirm its results via 
another technique like RT-qPCR. A biological replicate of RNA sequencing will reduce 
the number of false positives from the initial data. However, the gene transcription data 
have to be carefully interpreted since they do not necessarily reflect how the translation is 
affected. The antibody microarray gave a smaller number of host targets to look at as it 
analyzed the expression of only 812 proteins and phosphorylation of 262 amino acids. 
The regulation of these targets has to be confirmed with western blots since only 30 to 
45% of the changes in the protein levels detected by the antibody microarray can be 
reproduced by western blots according to Kinexus.  
Although the expression of katG increased in vitro in ROS treated knock-outs, the 
knock-outs were defective in upregulating katG expression in macrophages. One 
explanation for these results is that the ROS produced in vitro are much more than the 
amount in macrophages and thus can upregulate katG expression through different 
mechanisms that do not require the presence of Rv3165c or Rv3167c. If the amount of 
ROS added in vitro is dosed down, a difference in katG expression might be observed 
similar to the difference in macrophages. Another explanation is that Mtb needs Rv3165c 
and Rv3167c to respond to ROS in macrophages but not in vitro. This could be due to the 
presence of other factors in macrophages, such as pH and ingredients of the phagosome 
that only allow Rv3165c and Rv3167c to respond to ROS.  
Our lab previously tested a katG mutant to see its effect on host cell apoptosis. 
THP-1 macrophages infected with a katG mutant had significantly higher levels of 
apoptosis compared to wild type Mtb (149). However, this mutant (INH34 strain) also 
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lacked the neighboring genes Rv1907c, furA, Rv1910c, lppc, and fadB5 (181). A mutant 
strain that lacks only katG had a similar apoptotic phenotype as wild-type Mtb 
(Srinivasan L, unpublished data). These findings indicate that katG by itself is not 
essential for apoptosis inhibition by Mtb. In line with this idea, another graduate student 
in our lab, Jeff Quigley, showed that in addition to katG, other genes around katG 
mentioned above are not upregulated in Mtb in the absence of Rv3167c in macrophages. 
Therefore it is likely that Rv3167c acts as a regulator of katG and the other genes around 
it to prevent apoptosis. Quigley also showed that three sigma factors sigB, sigE and sigH 
were upregulated by Rv3167c in vivo.  Interestingly, katG and the genes around it that are 
regulated by Rv3167c contain putative binding sites for the same sigma factors regulated 
by Rv3167c according to the software Virtual Footprint (182). According to recent 
research ∆sigH infected macrophages were more apoptotic and had higher caspase-3 and 
7 activity compared to Mtb infected cells (183). These data suggest that Rv3167c 
regulates certain sigma factors (or regulators of sigma factors), which in turn regulate the 
other genes that are involved in inhibition of apoptosis. 
Although ∆katG inhibits apoptosis of THP-1 macrophages just like Mtb, ∆katG 
was less virulent compared to Mtb when they were used in infecting immunocompetent 
C57BL/6 mice (184). Complementation of katG restored the virulent phenotype in the 
same mice. When gp91 knock-out mice (no phagocyte superoxide production) were 
infected with Mtb and ∆katG, both strains showed similar virulence, suggesting that katG 
was involved in neutralizing peroxides produced by phagocyte NADPH oxidase and thus 
increasing the persistence of Mtb (184, 185). ∆katG did not replicate in murine bone 
marrow derived macrophages (BMDM) as well as Mtb but showed similar replication in 
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mice during the early stages of infection (184). This difference is probably due to the 
simplicity of one system versus the complexity of the other one that involve many 
different cell types. The seemingly conflicting results for katG deletion mutants may be 
due to different cell types used in vitro (THP-1 versus murine BMDM). It is possible that 
∆katG gives a phenotype that is different than Mtb only in murine cells. The apoptotic 
phenotype of ∆katG in the mouse lungs needs to be analyzed to further understand the 
decreased virulence of ∆katG. As mentioned before, although in addition to other 
proteins KatG secretion is also defective in secA2 knock-out Mtb (150), re-establishment 
of SodA secretion was enough to reverse the pro-apoptotic phenotype of secA2 mutant 
strain (146). This result also suggests that KatG is not involved in apoptosis inhibition. 
The requirement of Rv3165c for the upregulation of Rv3167c in macrophages 
indicates a possible mechanism whereby Mtb upregulates Rv3167c expression to possibly 
inhibit apoptosis and that this requires the presence or activity of Rv3165c to do so. 
Rv3165c might be interacting directly with Rv3167c. As another possibility Rv3165c 
might be interacting with another protein to increase the amount of Rv3167c. A detailed 
predicted model is discussed below. 
A working model for Rv3165c and Rv3167c emerged after the cellular 
localizations of these proteins were determined. Previous evidence showed that Rv3165c 
was required for Rv3167c expression, that both Rv3165c and Rv3167c were required for 
katG upregulation in infected macrophages and that ROS inhibition led to decreased 
apoptosis of ∆Rv3165c and ∆Rv3167c infected cells. In addition, Rv3167c is predicted to 
be a transcriptional regulatory protein. These results suggest the following working 
model, whereby Rv3165c resides in the plasma membrane and Rv3167c is in the 
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cytoplasm of Mtb. Without a signal that Rv3165c senses, the expression of Rv3167c is 
low (Figure 32A). When Rv3165c senses an extracellular signal that is thought to be 
either ROS or an oxidized molecule, it relays the signal directly or indirectly to Rv3167c. 
This relay causes an increase in Rv3167c expression (Figure 32B). Rv3167c then acts as 
a transcriptional regulator and upregulates expression of bacterial genes that inhibit 
apoptosis and downregulates the expression of bacterial genes that can induce apoptosis. 
Using either one or both of these strategies Mtb inhibits host cell apoptosis (Figure 32C). 
Bacteria employ protein sensors for ROS detection. Some of these sensors contain 
cysteine (C) in C-X-X-C (X is any amino acid) motifs. As the oxidation sensitive thiol 
groups of cysteines are oxidized, disulphide bonds are formed between the two cysteines 
in the motif, causing a conformational change of the protein structure and a change in the 
activity of the protein. Other bacterial sensors detect oxidative stress through iron via the 
Fenton reaction (Fe
2+ 






OH). Following detection of oxidative 
stress, these sensors go through modifications like oxidation of histidines, dityrosine 
formation or carbonylation (186). An example of these sensors is PerR, which is an iron-
dependent oxidative stress sensor of Bacillus subtilis that binds to iron or manganese in 
order to repress its target genes. Following a peroxide dependent stress, one of the 
histidines in the regulatory binding site of PerR becomes oxidized. This causes the 
release of iron from PerR followed by derepression of its target genes (187). Although 
Rv3165c does not contain a C-X-X-C motif, one of its extracellular amino acids 
predicted by TMHMM Server v. 2.0 is a histidine (Figure 29A). Histidine is one of the 












































Figure 32: The working model showing the confirmed localizations of Rv3165c and 
Rv3167c and their predicted functions. Rv3165c is localized to the cell envelope and 
predicted to sense a signal and relay this signal to Rv3167c. This relay of the signal 
causes an increase in Rv3167c transcription and translation. Increased amounts of 
Rv3167c causes upregulation of bacterial components that inhibit host cell apoptosis.  
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to a change in the three dimensional structure of the protein (188, 189). Therefore, it is 
possible that, like the iron-dependent oxidative sensors, ROS production by the host cell 
changes the structure of Rv3165c through oxidation of the extracellular histidine and this 
change in the structure either enables Rv3165c to interact with Rv3167c or with another 
protein that relays the signal to Rv3167c. Complementation of ∆Rv3165c mutant with 
Rv3165c lacking the extracellular histidine will show the importance of that amino acid 
in signal sensing. 
One of the other mechanisms of signal detection by Rv3165c may be via another 
membrane protein that interacts with Rv3165c and has an extracellular signal sensing 
domain. This other protein can sense the signal through ligand binding or another 
mechanism and relay the signal to Rv3165c. Identifying proteins that can interact with 
Rv3165c through techniques like bacterial two-hybrid system will help validate this 
signal detection pathway.  The points to investigate to prove this model include showing 
a direct or an indirect interaction between Rv3165c and Rv3167c, showing that Rv3167c 
regulates expression of other bacterial genes to inhibit host cell apoptosis and that 
Rv3167c binds to genomic DNA of Mtb to regulate gene expression. TMHMM Server v. 
2.0 predicts that for the two-component regulatory system sensors mprB, mtrB, phoR, 
prrB, senX3, trcS the number of extracellular amino acids varies from 273 to 504 
(compared to 3 for Rv3165c) (190–195). The lack of such a big extracellular amino acid 
stretch of Rv3165c suggests a different mechanism for signal detection by Rv3165c. In 
addition, according to InterProScan Rv3165c does not have a predicted histidine kinase 
domain (172) like the sensors of two-component systems (196, 197).  
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According to InterProScan, Rv3167c lacks any sensor or kinase domain and 
contains an amino terminal TetR-type DNA-binding helix-turn-helix domain and a 
carboxy terminal TetR-like transcriptional regulator domain. Lack of a kinase or sensor 
domain indicates that Rv3167c is not a member of Ser/Thr/Tyr protein kinases or one-
component systems that are responsible for many signal transduction pathways (198, 
199). All TetR family transcriptional regulators are homodimers and most of them 
repress transcription of genes (173). As such, demonstration of homodimer formation by 
Rv3167c will further confirm its classification as a transcriptional regulator. The 
sequence Rv3167c binds to needs to be identified via methods like chromatin 
immunoprecipitation in order to characterize it as a repressor or activator of gene 
transcription. Predicted DNA binding sequences for Rv3167c can be used in 
electrophoretic mobility shift assays to determine if Rv3167c binds to those sequences. 
However, the conditions under which Rv3167c binds to DNA may not be replicated in 
vitro and this might lead to false negative results. 
The preliminary data from the SCID mice infection experiment suggest that 
∆Rv3167c is not less virulent than Mtb and the guinea pig infection experiment data 
suggest that ∆Rv3167c and ∆nuoG are not less virulent than Mtb. Both of these 
experiments need to be repeated in order to confirm these results. The number of 
∆Rv3167c and its apoptotic phenotype in the lungs of the SCID mice have to be 
determined to make a better correlation between its apoptotic phenotype and virulence.   
It is possible that ∆Rv3167c does not have a pro-apoptotic phenotype in the phagocytic 
cells of mice and this leads to a similar virulence as wild-type Mtb. Our lab has identified 
a DNA region of Mtb that was required for inhibition of apoptosis in THP-1 
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macrophages, whereas lack of this region did not lead to loss of virulence of Mtb in mice 
(Velmurugan, K. unpublished data). However, the lack of 7/10 region from Mtb led to 
decreased virulence in SCID mice (Figure 8). On the other hand, that was a single 
experiment and infection experiments in SCID mice and guinea pigs for ∆Rv3167c 
together present a stronger case. If the decreased virulence of ∆7/10 and similar virulence 
of ∆Rv3167c (and ∆Rv3165c) compared to Mtb are confirmed, then this would suggest 
that the other genes in the 7/10 region may be involved in the virulence of Mtb. 
In contrast to the guinea pig infection results, ∆nuoG is less virulent in 
immunocompromised SCID and immunocompetent BALB/c mice (147). But when 
immunocompetent C57BL/6 mice were infected via aerosol route with Mtb and ∆nuoG, 
∆nuoG did not show any decreased virulence for up to 7 weeks as measured by bacterial 
counts (Miller J. and Gurses S., unpublished data). Keeping in mind that the guinea pig 
experiment was also done by aerosol infection whereas the SCID and BALB/c mice 
infections were done intravenously via a lateral tail vein, the physiologically more 
relevant experiment would be the one done by aerosol route since that allows Mtb to gain 
access to the lungs first. In addition, the guinea pig is considered to be a better model 
than the mouse to study Mtb infection (200, 201). The mouse infections that showed that 
∆7/10, ∆sodA and ∆katG were less virulent than wild-type Mtb were also done by 
injection of mycobacteria intravenously via a lateral tail vein (151, 184). It is possible 
that injection of mycobacteria into the animals, especially mice, is not a good model to 
study virulence of pro-apoptotic mutants and the differences that were observed in the 
virulence of the pro-apoptotic mutants were due to characteristics of tail vein injections 
(e.g., high dose of mycobacteria and a different route and spread pattern of mycobacteria 
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inside the animal). The different set of cells that the pro-apoptotic mutants encounter 
following a tail injection might be more affective in mounting a response against them 
than the cells they encounter following an aerosol infection, which might explain why 
pro-apoptotic Mtb mutants would seem to be less virulent in infections via tail vein 
injections. Although pro-apoptotic mutants might show differences in various terms in 
infections of cultured cells or cell lines compared to Mtb, they might not make a 
difference in vivo. To compare the two ways of infection, either ∆Rv3167c can be used 
for infection of mice via tail vein injection or the pro-apoptotic mutants that were shown 
to be more virulent can be used for infection of mice or guinea pigs via aerosols. If 
∆Rv3167c is found to be more virulent or the other pro-apoptotic mutants are found to be 
similarly virulent as Mtb in these experiments, it would suggest that mouse infections via 
tail vein injection do not give accurate results in terms of the virulence of pro-apoptotic 
Mtb mutants. This would also suggest that Mtb pro-apoptotic mutants are not good 
candidates for new vaccines and other phenotypes of Mtb that can elicit a better immune 
response have to be studied.     
Apoptosis of cultured murine and human macrophages following infection 
decreases the viability of mycobacteria (135, 137, 143). However, a recent study found 
that during the initial stage of an in vivo infection the viability of pro-apoptotic ∆nuoG 
mutant did not decrease after apoptosis of infected cells. The ∆nuoG mutant spread to a 
higher number of lung myeloid cells but was present in a lower number in each cell 
following infection of immunocompetent C57BL/6J mice (202). ∆nuoG infection lead to 
an earlier activation of CD4
+
 T cells compared to Mtb. Therefore the seemingly more 
virulent phenotype of the ∆Rv3167c mutant in the SCID mice might be due to the spread 
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of ∆Rv3167c to a higher number of cells through apoptosis and lack of the adaptive 
immune response. The number of ∆Rv3167c bacteria was higher than the number of Mtb 
in the guinea pig lungs by day 28 but they were not significantly different by day 56. 
Compared to Mtb, ∆Rv3167c infected guinea pig alveolar macrophages go through 
higher rates of apoptosis (Hurley B., unpublished data).  Therefore, it is possible that 
∆Rv3167c replicated and possibly spread better than Mtb through apoptosis in the early 
stages of infection followed by a better control of mycobacterial infection by the guinea 
pigs through adaptive immunity that led to a decrease in the number of bacteria.  
In conclusion, I identified two novel anti-apoptotic genes of Mtb that will be 
added to a short list of anti-apoptotic genes. Several effects of deleting these genes were 
identified in Mtb as well as in THP-1 macrophages. However, the infection experiments 
showed that the virulence of one of the mutants, ∆Rv3167c, was not less than wild-type 
Mtb as expected from a pro-apoptotic mutant. Although this lack of difference in the 
virulence phenotype might be specific for ∆Rv3167c, it is also possible that infection 
experiments done to show the virulence of other pro-apoptotic mutants were flawed. 
Confirmation of virulence phenotypes of previously found pro-apoptotic mutants via 
aerosol infection of mice and/or guinea pigs is suggested, as that method of infection is 
the more physiologically relevant one. On the other hand, if the decreased virulence of 
pro-apoptotic mutants is not confirmed through aerosol infections, this could mean that 
apoptosis inhibition by Mtb is irrelevant in terms of its virulence. 
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